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WiTness seMinaRs: 
MEETINGS AND PUBLICATIONS
 1
In 1990 the Wellcome Trust created a History of Twentieth Century Medicine 
Group, associated with the Academic Unit of the Wellcome Institute for the 
History of Medicine, to bring together clinicians, scientists, historians and others 
interested in contemporary medical history. Among a number of other initiatives 
the format of Witness Seminars, used by the Institute of Contemporary British 
History to address issues of recent political history, was adopted, to promote 
interaction between these different groups, to emphasize the potential benefits 
of working jointly, and to encourage the creation and deposit of archival sources 
for present and future use. In June 1999 the Governors of the Wellcome Trust 
decided that it would be appropriate for the Academic Unit to enjoy a more 
formal academic affiliation and turned the Unit into the Wellcome Trust Centre 
for the History of Medicine at UCL from 1 October 2000. The Wellcome Trust 
continues to fund the Witness Seminar programme via its support for the Centre.
The Witness Seminar is a particularly specialized form of oral history, where several 
people associated with a particular set of circumstances or events are invited to 
come together to discuss, debate, and agree or disagree about their memories. To 
date, the History of Twentieth Century Medicine Group has held nearly 50 such 
meetings, most of which have been published, as listed on pages xiii–xvi.
Subjects  are  usually  proposed  by,  or  through,  members  of  the  Programme 
Committee of the Group, which includes professional historians of medicine, 
practicing scientists and clinicians, and once an appropriate topic has been agreed, 
suitable participants are identified and invited. This inevitably leads to further 
contacts, and more suggestions of people to invite. As the organization of the 
meeting progresses, a flexible outline plan for the meeting is devised, usually with 
assistance from the meeting’s chairman, and some participants are invited to ‘set 
the ball rolling’ on particular themes, by speaking for a short period to initiate and 
stimulate further discussion.
Each meeting is fully recorded, the tapes are transcribed and the unedited transcript 
is immediately sent to every participant. Each is asked to check his or her own 
contributions and to provide brief biographical details. The editors turn the transcript 
1  The following text also appears in the ‘Introduction’ to recent volumes of Wellcome Witnesses to Twentieth 
Century Medicine published by the Wellcome Trust and the Wellcome Trust Centre for the History of 
Medicine at UCL.x
into readable text, and participants’ minor corrections and comments are incorporated 
into that text, while biographical and bibliographical details are added as footnotes, 
as are more substantial comments and additional material provided by participants. 
The final scripts are then sent to every contributor, accompanied by forms assigning 
copyright to the Wellcome Trust. Copies of all additional correspondence received 
during the editorial process are deposited with the records of each meeting in archives 
and manuscripts, Wellcome Library, London. 
As with all our meetings, we hope that even if the precise details of some of the 
technical sections are not clear to the non-specialist, the sense and significance 
of the events will be understandable. Our aim is for the volumes that emerge 
from these meetings to inform those with a general interest in the history of 
modern medicine and medical science; to provide historians with new insights, 
fresh material for study, and further themes for research; and to emphasize to 
the participants that events of the recent past, of their own working lives, are of 
proper and necessary concern to historians.
Members of the Programme committee of the  
history of Twentieth century Medicine Group, 2009–10
Professor Tilli Tansey – professor of the history of modern medical sciences, 
Wellcome Trust Centre for the History of Medicine at UCL (WTCHM) and chair
dr sanjoy bhattacharya – reader in the history of medicine, WTCHM
sir christopher booth – former director, Clinical Research Centre, 
Northwick Park Hospital, London
dr John ford – retired general practitioner, Tonbridge
Professor Richard himsworth – former director of the Institute of Health, 
University of Cambridge
Professor Mark Jackson – professor of the history of medicine and director, 
Centre for Medical History, Exeter
Professor John Pickstone – Wellcome research professor, University of Manchester
Mrs lois Reynolds – senior research assistant, WTCHM, and organizing secretary
Professor lawrence Weaver – professor of child health, University of Glasgow, and 
consultant paediatrician in the Royal Hospital for Sick Children, Glasgowxi
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inTRodUcTion
The medical use of cannabis has a very long history; it was used for thousands 
of years in Indian and other Asian medicine and was first introduced to 
the west in the mid-nineteenth century by a brilliant young doctor, W B 
O’Shaughnessy, returning to England after service in India. Cannabis was 
taken up enthusiastically by physicians in Europe and the US and was widely 
used for almost a hundred years until it fell out of favour as new and more 
easily standardized medicines became available and government regulations 
were imposed.  Tincture of cannabis finally left the British Pharmacopoeia in 
the mid-1970s.
This Witness Seminar, however, was focused not on this early history but on 
the resurgence of interest in medical cannabis that has occurred in the past few 
decades. It brought together a group of people with diverse expertise who had 
witnessed at first hand the development of this field.  Although the seminar 
did not deal at all with the recreational use of cannabis, it is impossible to 
consider the history of medical cannabis without considering the impact 
that the rapid growth of the illicit recreational use of the drug in the latter 
part of the twentieth century has had. The ‘cannabis wars’ have been fought 
between those who believe it to be harmless and medically useful, and those 
who see it as a danger to health and to society without any legitimate medical 
use. For many years the stigmatization of cannabis had a negative influence 
on the availability of research funding and promoted reluctance on the part 
of doctors and pharmaceutical companies to be involved in research on the 
medical uses of cannabis.
This changed, at least temporarily, with the elucidation in 1973 by Raphael 
Mechoulam of the structure of THC as the principal active ingredient of cannabis. 
A number of pharmaceutical companies began active research programmes aimed 
at designing THC-like synthetic compounds that would retain the medical 
benefits of THC without having the unwanted psychoactive effects. Such a 
separation was never achieved, although several very potent synthetic cannabinoids 
were synthesized and proved valuable later as research tools. Only one licensed 
drug, Nabilone
®, emerged from all this effort (page 17). THC itself underwent 
successful clinical trials as an antiemetic and as a treatment for ‘AIDS wasting 
syndrome’ and was approved as a prescription medicine with the trade name 
Marinol
®(page 5). Neither product made much impact, however, and interest in 
the medical uses of cannabis fell to a very low level for more than a decade.xx
The discovery of THC and the potent synthetic cannabinoids, together with 
the development of synthetic antagonists, such as rimonabant, sparked the 
modern revival of research interest in the field. Many of the key players in 
this were able to provide first-hand descriptions of the research discoveries 
that followed. New animal behaviour models were developed to investigate 
the psychomotor, analgesic and reward properties of cannabinoids. A major 
step forward was the discovery and cloning of the CB1 receptor in the brain 
and the demonstration that it mediated the principal psychoactive actions of 
cannabis (page 17). This was followed by the discovery of the CB2 receptor 
in the immune system in the periphery and further development of CB1 and 
CB2-selective ligands. As with the discovery of the opiate receptors 20 years 
earlier, this new knowledge prompted a search for possible endogenous ligands 
for the cannabinoid receptors, and this culminated in the discovery of a family 
of naturally occurring lipid signalling molecules, the endocannabinoids. Roger 
Pertwee, who with Raphael Mechoulam played a key role in this discovery, 
related how his work on the first endocannabinoid, anandamide, was 
performed in the same laboratory in Aberdeen used by John Hughes when he 
discovered the enkephalins 20 years earlier (page 16). 
This avalanche of new scientific information was not accompanied at first by 
any revival of interest in the medical uses of cannabinoids. This happened 
partly as an unexpected by-product of the rapid growth in the recreational 
use of cannabis on both sides of the Atlantic during the 1980s and 1990s. 
As seminar speakers emphasized, the increasing number of self-reports of 
the beneficial actions of cannabis in treating the symptoms of a number of 
intractable disorders began to have a significant impact. Anonymous surveys 
such as that conducted by the Multiple Sclerosis (MS) Society revealed that 
a surprising number of  MS patients were willing to use the illegal drug, and 
claimed medical benefits. The increasing level of interest in this possibility 
prompted a number of medical organizations to undertake reviews of the 
available evidence. The British Medical Association’s report was followed by an 
enquiry by the House of Lords Select Committee on Science and Technology, 
published in 1998. This was my own introduction to the field of cannabis 
research as I was privileged to act as scientific adviser to this group. Although 
these reports seemed to have little immediate impact, they imparted a degree 
of respectability to the concept of the medicalization of cannabis. The initial 
reports were followed by an extensive review by the US Institute of Medicine 
and more recently by the Royal College of Physicians.  All of these august 
bodies concluded that there was evidence for genuine medical applications of xxi
cannabis, but that more research was needed, particularly to supplement the 
sparsity of properly controlled clinical trial data.
This led to the sponsoring by the Medical Research Council of the first 
large-scale clinical trial of cannabis in MS, which recruited more than 600 
patients and lasted for up to 12 months. Although the results were mixed, 
there was evidence for a genuine, if modest, benefit on symptoms of pain and 
spasticity. The changing attitudes to medical cannabis also prompted Geoffrey 
Guy to form a company, GW Pharmaceuticals, to undertake the systematic 
development of a standardized herbal cannabis extract and a novel sublingual 
spray delivery system for the product called Sativex. Guy’s background in 
developing conventional pharmaceuticals and herbal medicines gave him 
the necessary experience to undertake this difficult task. In the seminar, he 
provided important insights into the courageous decisions taken by the Home 
Office and by the Medicines Control Agency to provide GW Pharmaceuticals 
with licences to grow a standard crop of cannabis plants, and to undertake 
clinical trials with what remained a Schedule 1 drug (pages 30–4 and 36–8). 
Sufficient clinical data was amassed with Sativex to persuade the Canadian 
Government to approve it as a prescription medicine for treating pain in 
MS patients, and the product may ultimately be approved in many other 
countries, including the UK. 
On the other side of the Atlantic, progress towards the medicalization 
of cannabis gathered pace towards the end of the twentieth century. The 
Canadian Government made a medicinal form of herbal cannabis available 
as a medicine, as the Dutch had done some years earlier (page 43). In the 
US, voters in several individual states approved the medicinal use of smoked 
cannabis, and ‘cannabis pharmacies’ were established, despite continuing 
resistance from the Federal Government in Washington (pages 42–3). The 
state of California in particular has led this movement, and provided state 
funds for controlled clinical trials. 
Seminar participants speculated on possible future developments in the field. 
International pharmaceutical companies are focusing major research efforts 
to develop CB2 receptor selective ligands as potential anti-inflammatory/
analgesic agents. The CB2 receptor is not associated with any psychoactive 
effects and is thus seen as ‘safe’. Pharmaceutical companies had great 
hopes for CB1 antagonists for the treatment of obesity, but the first to be 
developed, rimonabant, ended in an expensive failure (pages 5 and 42). 
There may, nevertheless, still be other applications of cannabinoid antagonist xxii
drugs. Meanwhile, research on the development of cannabis itself or novel 
compounds arising from endocannabinoid research remain largely the 
domain of smaller pharmaceutical or biotechnology companies or academic 
groups.  Nevertheless, the future for the medicinal applications of our new 
understanding of cannabinoid mechanisms looks bright.
leslie iversen
University of OxfordThe MedicalizaTion of cannabis 
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Professor Tilli Tansey: Good afternoon ladies and gentlemen and welcome to 
this Witness Seminar on ‘The Medicalization of Cannabis’. I’m the convenor 
of the History of Twentieth Century Medicine Group at the Wellcome Trust 
Centre for the History of Medicine at UCL. In 1990 the Wellcome Trust set 
up this group to create links between medical and scientific practitioners and 
historians of recent medicine and science. One of the techniques we devised 
is this format: the Witness Seminar, where we get together a group of people 
who’ve been involved in particular events, discoveries or debates, to discuss 
among themselves what really happened, the whys, hows and wherefores of 
what things went right and what things went wrong. We’ve now held over 50 
meetings and have published more than 38 of them. All of our meetings are 
freely available as downloadable pdfs on the website of the Wellcome Trust 
Centre for History of Medicine at UCL, so do please feel free to have a look at 
them, and to use them if they are of interest.
1 
We never get everybody we want to these meetings. What we hear this afternoon 
will be the reminiscences and debates of those of you who are here. There are 
undoubtedly gaps and we are well aware that we are not going to be able to 
cover everything. Four years ago, the Royal College of Physicians working party 
reported on cannabis and cannabis-based medicines. If I can just quote from 
the first point in the executive summary: 
This report is concerned with the potential benefits and risks to health 
from the use of cannabis and cannabis-based drugs as medicines, rather 
than with the moral or legal status of cannabis.
2
This focuses the way we want to structure our meeting this afternoon. We want 
to look at the benefits and possible risks to health from the use of cannabis as 
medicines, not any other aspect of cannabis. The topic was proposed by Professor 
Virginia Berridge, who has a postgraduate student working on a project in this 
field.
3 Virginia and I are going to chair this meeting between us; we are going 
to try to cover the early science and industrial and regulatory aspects, possibly 
devoting about 55 or 60 minutes to each subject. But before that, I’ll hand over 
to Virginia who is going to say a little bit more about her project.
1  Available at www.ucl.ac.uk/histmed/publications/wellcome_witnesses_c20th_med, or by following the 
links to publications from www.ucl.ac.uk/histmed. 
2    Royal  College  of  Physicians  (2005):  vii.  Available  at  www.rcplondon.ac.uk/pubs/books/cannabis/
cannabis_executive-summary.pdf (visited 12 January 2010).
3  See Taylor (2008).The Medicalization of Cannabis
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Professor Virginia  berridge:  This  derives  from  a  three-year  project,  which 
was funded by the Wellcome Trust history of medicine panel, on the factors 
that have aided or been concerned with the medicalization of cannabis since 
the 1950s, but in particular since the 1970s and 1980s. I was the principal 
investigator on that grant and Suzanne Taylor was the research student and she 
is currently completing a PhD on this topic. So this Witness Seminar comes at 
a very opportune time for her. We’re now going to hand over to Suzanne to give 
a brief historical introduction to this seminar. 
Ms suzanne Taylor: As Virginia said, I’m just going to give a very quick, potted 
history of the medical use of cannabis. Cannabis can be considered something 
of a curious boundary substance, capable of shifting between the categories 
of licit medicine and illicit drug, and back again, depending on the different 
scientific, cultural or political understandings of the day. Throughout its history, 
cannabis has been different things to different people, used as a medicine either 
through its extracts or as a leaf, it’s been something of a pain for policy-makers, 
but also valued as a pain reliever for people suffering from intractable diseases. 
For some, it’s been a harmless recreational drug, for others, a danger to mental 
health and, perhaps, society. As a medicine, cannabis was introduced to the UK 
from the colonies around the nineteenth century and it became something of a 
wonder drug, used for a variety of purposes, from alleviating vomiting caused 
by cholera and muscle spasm by rabies to use as a sedative or antibiotic.
4 But 
its usefulness was relatively short-lived. Cannabis’s active principle had not at 
that time been isolated, unlike in the case of the opiates. Also, because of its 
properties, particularly not being water-soluble, it wasn’t usable in new drug 
delivery systems with a hypodermic syringe, thus it slowly fell out of favour. 
There were also concerns about its link to insanity and crime.
5 So, research 
really fell by the wayside. 
It was in the 1960s, when it re-emerged as a recreational drug in the counter-
culture, that interest was renewed in the scientific community, perhaps through 
4  See, for example, O’Shaughnessy (1839a); Mills (2003); Berridge (2003).
5  Dr Edward Gill wrote: ‘Cannabis was incorporated in the UK Dangerous Drugs Act (DDA) of 1925, 
on the same footing as opium. The DDA was the UK enactment of the League of Nations’ International 
Opium Convention, 19 February 1925, which was debated at the Second Opium Conference in Geneva, 
November 1924–February 1925. This convention was really about the regulation of the traffic in opium, 
but at the last minute there was an impassioned appeal by the Egyptian delegate that cannabis was socially 
harmful and it was included in the convention, almost as an afterthought. There is an account of this as an 
appendix to the Wootton report.’ E-mail to Mrs Lois Reynolds, 26 June 2009. See www.ukcia.org/research/
wootton/apII.php (visited 22 February 2010); Berridge (1999); Mills (2007). The Medicalization of Cannabis
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interest in drug dependence.
6 Also, importantly, the active principle, THC 
(tetrahydrocannabinol), was isolated and the pharmacology of cannabis could 
proceed apace.
7 With wider use in the general public, anecdotal reports of its 
usefulness in the treatment of disease began to emerge. But running parallel to 
this renewed interest in the science was increasingly prohibitive international 
legislation, for example, the 1961 UN Convention on Narcotic Drugs, and 
increasing regulation within the UK, and tincture of cannabis was banned by the 
mid-1970s.
8 With research on the pharmacology having taken off, but not much 
progress on the mode of action and other drugs beginning to take precedence 
in concern and increasing legislation, research interest began to contract again, 
though  in  the  1980s  we  saw  the  introduction  of  synthetic  cannabis-based 
drugs for the treatment of nausea caused by cancer chemotherapy, for example 
Marinol
® (dronabinol).
9 In the late 1980s and early 1990s there were important 
breakthroughs with the discovery of the cannabis receptor and the endogenous 
cannabinoids.
10 This opened up new avenues for research and stimulated interest 
in the field. Thus by the late 1990s, early 2000, we saw the re-emergence of 
pharmacological interest. A particular interest in the UK was the development 
of GW Pharmaceuticals, which was interested in the extracts of cannabis for 
the treatment of multiple sclerosis (MS) and pain.
11 We saw the start of clinical 
trials, developing an evidence base to support the anecdotal reports. 
Also  important  throughout  this  history  has  been  the  role  of  the  patient 
perspective and the use of self-medication. Activism in the UK related more to 
MS and pain, where people have pressured for more research, clinical trials and, 
perhaps, in the meantime, access to cannabis itself. So, today we’re interested in 
6  See, for example, World Health Organization (1971); Home Office (1968).
7  Mechoulam et al. (1970). See also Mechoulam and Hanuš (2000); Di Marzo (2006); Pertwee (2006).
8  The United Nations Conference for the Adoption of a Single Convention on Narcotic Drugs met at UN 
Headquarters, New York, NY, 24 January–25 March 1961; see United Nations (1972). 
9        Marinol is an antiemetic produced by Unimed Pharmaceuticals, a subsidiary of Solvay Pharmaceuticals 
Inc.,  Marieta,  GA,  see  www.solvaypharmaceuticals-us.com/products/marinolproductinformation/ 
0,998,12413-2-0,00.htm  (visited  13  January  2010).  For  results  of  clinical  trials  published  in  2005 
and  2006  see  www.solvaypharmaceuticals.com/researchanddevelopment/clinicaltrialsdisclosure/
ClinicalTrialResultsDatabase/Marinol/0,,63138-2-0,00.htm (visited 13 January 2010). See pages 18 and 42. 
10  Matsuda et al. (1990).
11  GW Pharmaceuticals was founded in 1998 in Salisbury, Wiltshire by Dr Geoffrey Guy and Dr Brian 
Whittle. It was floated on the London Stock Exchange AIM market in 2001. See pages 34–8.The Medicalization of Cannabis
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the process of the medicalization of cannabis, considering themes including the 
trajectory of research, the importance of the growing international regulation, 
the role of industry, the preparation for clinical trials and the importance of 
activism. Within these themes perhaps factors to consider would include the 
importance of technological change, the development of drug delivery systems, 
the debate over extracts versus synthetics and issues of funding and supply. I’ll 
hand over to Tilli Tansey, who will be chairing the first section on the early 
science, THC and receptors.
Tansey: As we start looking at the process of medicalization and the trajectory of 
research about what really happened and how, I’m reminded of Peter Medawar’s 
paper, ‘Is the scientific paper a fraud?’ suggesting that the way we write scientific 
papers is constrained by the actual format and one never really knows the fine 
detail of what went on, how and why.
12 So, we want to ask you to tell us what 
was going on in the 1950s, 1960s and 1970s in the labs conducting the early 
research on cannabis. We have a number of pioneers here, people who were 
there at the time. We have already asked one or two people to say a few words to 
begin with, but please comment and add your own reminiscences and debates. 
Perhaps I could ask Professor Mechoulam to make some comments to begin 
with? 
Professor Raphael Mechoulam: Cannabis has been used as a medicine for 
thousands of years. I understand we’re not going into that aspect, but there is 
quite a lot of literature on it, some of it published, some of it just mentioned.
13 
I understand that we are not going into the historical use of cannabis over 
centuries or millennia. 
Tansey: No, we would really like to hear people’s personal witness experiences.
Mechoulam: Suzanne Taylor mentioned that as cannabis became a drug used by 
young people in the 1960s, it led to the investigation of cannabis as it had not 
been investigated before. Actually, a lot of work had been done on it previously, 
but, surprisingly, the active component or components of cannabis had not 
been identified.
Here I come to something personal – I understand that this is what is asked 
for: in the early 1960s I was back in Israel after my first postdoctoral visit to 
the US, where I was at the Rockefeller Institute, New York, NY, working on 
12  Medawar (1963).
13  See, for example, Russo (2005); Mathre (ed.) (1997).The Medicalization of Cannabis
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natural products. I returned to the Weizmann Institute of Science, Rehovot, 
Israel, where, at that time – and it’s still the procedure today – a young person 
who is appointed has to come up with a few projects and then goes on working 
on them alone, or if he gets money, with some help. After five or six years 
the academic board at the Weizmann Institute decides whether he has done 
significant work in the field he has chosen. Then they may, or may not, give 
him tenure. As I mentioned, I had just come back from the US and I was 
interested in the chemistry and biological effects of natural products, and chose 
a few topics, one of which was cannabis. I asked the National Institutes of 
Health (NIH) in 1961/2 to support Dr Yehiel Gaoni and me.
14 The head of 
pharmacology at the National Institute of Mental Health (NIMH), Dr Daniel 
Efron, told me that they hadn’t awarded a single cannabis grant; they were not 
interested in cannabis; they thought that it was a drug used mostly in Mexico 
and South America: ‘It’s not an American problem; when you come up with 
something  more  significant  and  relevant,  please  call  us.’  Nevertheless,  my 
colleague, Dr Yehiel Gaoni, who was more or less at the same stage as I was 
at the Weizmann Institute, and I went ahead. We joined hands and started 
working together on the topic. About a year later, I got a call from Dr Efron 
asking me whether I was still working on cannabis and when I said: ‘Yes,’ he 
asked, ‘Can I come over?’ So, he came over and I inquired: ‘What’s the rush?’ 
He said: ‘Well, a senator called us and asked whether cannabis will ruin his son’s 
brain because he was caught smoking pot.’ The senator asked the NIH whether 
they had any medical or physiological information on cannabis. They had 
none, because nobody was working on it; they hadn’t given a single cannabis 
grant ever, I believe, maybe a decade previously, but anyway, at that time, they 
had no projects. By that time we had isolated THC and elucidated its structure. 
Dr Efron took with him the world’s supply of THC, about ten grams. Quite 
a bit of the early pharmacological work in the US on THC was done with the 
material that Dr Efron got from us and NIH was happy.
15 We got a grant and 
then later had to reapply many times; the grant continued for nearly 40 years, 
14  Professor Raphael Mechoulam wrote: ‘Yehiel Gaoni gained a PhD at the Sorbonne, Paris. He joined 
the Weizmann Institute in the early 1960s. He worked with Professor F Sondheimer on the syntheses of 
annulenes, a very important group of compounds. We collaborated on the chemistry of cannabinoids for 
about five or six years until I moved to Jerusalem. He retired as a professor of chemistry at the Weizmann 
about 15 years ago.’ E-mail to Ms Stefania Crowther, 9 March 2010. Dr Yehiel Gaoni discusses his research 
on THC in the film, Waiting to Inhale (dir. Jed Riffe, 2005).
15  Professor Raphael Mechoulam wrote: ‘Personal communication from the late Dr Monroe Wall, who 
worked on THC at the time, and from the late Dr Daniel Efron.’ Note on draft transcript, 9 March 2010.The Medicalization of Cannabis
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and this was my main source of support. This is how my work began. There 
was not a lot of interest in cannabis when we started working on it. We began 
research on cannabis because it seemed strange that an illicit drug, widely used, 
was not as well known as morphine and cocaine. It was 150 years behind its 
time. There were good technical reasons why it was not known.
Morphine and cocaine are alkaloids, so they produce salts, which are crystalline 
and can be purified easily. In contrast, THC is part of a huge group of cannabinoids 
present in the plant; all of them boil at more or less the same temperature so they 
were very difficult to separate with the techniques available in the nineteenth 
and early twentieth centuries, and therefore the active component had not been 
isolated. At that time, only the structure of cannabinol, one of the components, 
was known and had been investigated quite thoroughly. It had been isolated in the 
UK in Cambridge at the end of the nineteenth century.
16 The structure was more 
or less completed, again in the UK, in the mid-1930s, more or less – not fully. 
It was fully identified and elucidated by Alex Todd (Lord Todd of Trumpington 
from 1962) in the UK and Roger Adams in the US, in the late 1930s and early 
1940s.
17 But that was the one compound that was really well known, and as it is 
a compound formed on oxidation of THC, it’s probably not an actual natural 
product. Another compound that had been isolated was cannabidiol, but its 
structure was not fully known (see Appendix 1). So, it seemed that the best thing 
for us to do was to re-isolate cannabidiol, a crystalline compound, and elucidate 
its structure. This was our first paper on the cannabis constituents.
18 We then went 
on isolating and elucidating the structures of a lot of the compounds that are there 
– cannabigerol, cannabichromene, cannabicyclol and cannabinoid acids.
19 
The reason that we could do this was that techniques had improved. There were 
new chromatography techniques that were available. At that time, almost 50 
years ago, they were considered well advanced. And there were also techniques 
for elucidating the structures that were not available in the 1920s or 1930s, like 
nuclear magnetic resonance and mass spectrometry. So, we had the techniques 
both for separation and for elucidating the structures, and that is what we 
did.  We  isolated  delta-9-tetrahydrocannabinol  (delta-9-THC)  in  1963  and 
16  Cannabinol was first isolated in Cambridge, published as Wood (1899), but was incorrectly assumed to 
be the active ingredient of cannabis. See also Mechoulam and Hanuš (2000).
17  See Work et al. (1939); Todd (1946). See also Maddox (1997); Mechoulam (1997); Adams (1940, 1941).
18  Mechoulam and Shivo (1963). 
19  See Mechoulam (ed.) (1973); Iversen (2000); Pertwee (ed.) (2005); Pertwee (2006).The Medicalization of Cannabis
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published the identification in 1964; we called it at that time delta-1-THC. 
We elucidated the structure mostly by physical measurements. We showed that 
there is essentially only one psychoactive compound: previously, people didn’t 
know whether there was one compound or a number of compounds that were 
active. And this compound thus became available. Pharmacologists don’t like 
to work with mixtures, for obvious reasons, but did a lot of work with the 
compound that we had isolated and which we supplied to many researchers. 
We devised later (and there was another group at that time in Switzerland that 
did the same) a synthetic pathway to natural THC, which is a (-) enantiomer I 
mean it rotates light to the left.
20 By our method one can also synthesize the (+) 
enantiomer, and this, I think, is still the only synthesis which does both things, 
and both enantiomers were evaluated at that time. 
Another point: how does the plant synthesize these compounds? These are not 
very complicated compounds from the point of view of a chemist, and yet 
there is only one plant that synthesizes cannabinoids; the Cannabis sativa. Very 
strange. The cannabinoids are simple compounds and there are lots of them 
in the plant; about 60 are known. We isolated most of the major ones and 
biosynthetic pathways emerged. It was quite obvious how these compounds go 
from one into the other in the plant. Alex Todd had done some work on that, 
but he didn’t have the actual compounds – hence it was very difficult for him. 
Surprisingly, Alex Todd left the field in the early 1940s and went into other 
things for which he got the Nobel prize; so his interest waned.
21 And, surprisingly 
again, there was essentially no competition at that point. There was almost no 
work on the chemistry of the cannabinoids in the early 1950s, no work in the 
late 1950s, there was a little bit of interest in the early 1960s, but essentially no 
work was done, which was very, very surprising.
Tansey: May I ask Dr Gill what was the impact of the discovery of THC? 
dr edward Gill: Well, I can more easily answer that by saying how the Oxford 
group, of which I was one, got involved in it. I think the trigger as far as 
Oxford was concerned was that c. 1970-ish, a report had been commissioned 
and published, known as the Wootton report (the subcommittee was chaired 
by Baroness Wootton). It may have been concerned with other things as well, 
but it was essentially addressing the question of whether cannabis should be 
20  Petrzilka et al. (1969).
21  See Brown and Kornberg (2000).The Medicalization of Cannabis
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decriminalized or not.
22 At that point, I think as far as Wootton was concerned, 
they were very much inclined to take the view that the inclusion of cannabis in 
the Dangerous Drugs Act (DDA) was causing more harm than good. They were 
therefore inclined to recommend that cannabis should be withdrawn from the 
DDA. That provoked a letter from Professor Sir William (Bill) Paton, who was 
then the head of the Oxford pharmacology department, to Baroness Wootton 
effectively agreeing with what Raphael Mechoulam has just said, which was 
that this was actually a very rash recommendation given that there was in fact 
very little known about cannabis; there was very little hard scientific evidence 
available in the literature to support a judgment one way or the other. Therefore, 
in a sense, it was considered to be more prudent to leave things as they were. 
That led to an obvious retort from Wootton back to Paton to the effect that: 
‘Well, if there isn’t that much pharmacology, isn’t it about time that you did 
some?’ And that is how we started on it. 
We needed a sample of THC, which was then recognized as the principal 
active constituent. There was no obvious source, so it was a question of doing 
it yourself. By trade I am a chemist, although I was based in the pharmacology 
22  Home Office, Advisory Committee on Drug Dependence (1968); the chairman was Sir Edward Wayne. 
The report includes the report on cannabis by the hallucinogens subcommittee chaired by Baroness Wootton 
of Abinger. 
figure 1: Tincture of cannabis, manufactured by William Ransom and son ltd. The Medicalization of Cannabis
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department and I came into it simply as an exercise in natural product chemistry. 
Most of my work up until then had been on straight synthetic chemistry so I 
really regarded it as an exercise in natural product isolation. Fortunately, a lot of 
the work had already been done by Raphael Mechoulam and others, so it was a 
relatively straightforward exercise to isolate pure THC. There was a firm called 
Ransom that had the country’s entire stock of tincture of cannabis at that time 
(Figure 1).
23 So my job there was simply to isolate a sample of pure THC. 
To carry the story on a bit, we used column chromatography to isolate a crude 
sample of THC and then, at the final stage, a method known as countercurrent 
distribution. I won’t go into it, but it’s essentially a multiple solvent extraction 
procedure, which has the advantage that it can be scaled up quite easily to handle 
gramme quantities.
24 I isolated a main fraction and identified it as THC from 
its mass spectrum, among other things. There was a second peak that emerged 
from the countercurrent machine, which I put aside at that stage. Having got the 
sample of THC I then thought: ‘I wonder what this slow-running component 
is going to be?’ I isolated it, took its infrared spectrum, which was at first glance 
identical with that of THC, which caused, I must say, an absolute panic on my 
part. I thought: ‘Oh gosh, I’ve got the samples muddled up!’ But we pursued 
it and found that this actually contained the propyl homologue of THC, with 
the terminal carbon chain shortened by two carbon atoms (see Appendix 1).
25 
It turns out that other people had seen traces of the propyl homologue in mass 
spectra, but Ransom’s sample had come from Pakistan and was very unusual, in 
that there were roughly equal amounts of the propyl homologue and THC itself. 
23  Professor Roger Pertwee wrote: ‘Tincture of cannabis was a commercial product that was prepared 
from Cannabis sativa grown in Pakistan and imported into the UK under licence. See Gill et al. (1970).’ 
E-mail to Ms Stefania Crowther, 8 March 2010. William Ransom and Son was established in 1846 in 
Hitchin, Hertfordshire, and produced extracts of cannabis for pharmaceutical use until prohibited by 
law in 1973. Since 2005 the company’s development team has been part of an EU-funded consortium 
researching the application of cannabis extracts to treat rheumatoid arthritis and migraine. See www.
williamransom.com/about_us.asp?pid=4&nid=153; www.williamransom.com/research_and_development.
asp?nid=198&pid=47cannabis;  http://eprints.pharmacy.ac.uk/401/1/Heinrichcannabisforum.pdf  (sites 
visited 18 January 2010).
24  Dr Edward Gill wrote: ‘Countercurrent distribution is a liquid–liquid partition system whereby a train 
of up to 100 interconnected glass tubes is mounted on a rack and mechanically agitated, and a substrate is 
repeatedly partitioned between two immiscible solvents moving in opposite directions… Countercurrent 
distribution is not widely used nowadays, being superseded by high performance liquid chromatography.’ 
E-mail to Ms Stefania Crowther, 1 March 2010. See Ito and Bowman (1970); Korte and Sieper (1965).
25  Gill et al. (1970); Gill (1971).The Medicalization of Cannabis
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Roger Pertwee can say much more about the pharmacology that we were doing 
in the department at that time. As far as my own group was concerned, we 
were interested in whether the biological activity could be solely attributable 
to THC, or whether it was due to a metabolite. It was known that THC was 
hydroxylated in the seven position, and we, Roger particularly, did some work 
where we came to the conclusion that the metabolite, the 7-hydroxy, did make a 
contribution to the pharmacology of cannabis, but wasn’t, as has been suggested, 
totally responsible for it; it was roughly half and half. I think at that point, as 
far as my group was concerned, we got to the point of saying: ‘Well, there it 
is.’ Roger and Bill Paton had worked out the catalepsy assay and had explored 
the basic pharmacology.
26 We came to the conclusion that cannabis probably 
could be classified as among the group of lipophilic general anaesthetics, very 
non-polar, as Raphael Mechoulam said, so totally different in its physical and 
chemical properties from the other centrally-acting alkaloids. We did some 
work with spin labeled phospholipids bilayers and showed that THC produced 
the same sort of perturbation (fluidization) of membrane lipid bilayers as other 
non-volatile anaesthetics, e.g. alphaxalone, did.
27 
At that point, my group withdrew from the field. I think the trigger, as far as the 
Oxford group was concerned, was very much the Wootton report and the fact 
that quite a lot of the hard work had already been done as far as the isolation 
was concerned. Raphael had completed the structure determination and there 
were several procedures available in the literature for its isolation, so it was 
simple to follow up this work, get hold of some pure THC and then start doing 
pharmacology.
28
Tansey: Who was funding the research? 
Gill: Most of it was funded out of departmental resources. The MRC did support 
it subsequently, but in those days departments could afford to do some research 
out of their own resources. 
Tansey: Oh yes, golden, golden days! 
Gill: Those were the days. As far as my group was concerned, it wasn’t until 
much later on that we used grant money. We had MRC student support grants, 
but as far as the actual funding of the research is concerned, my impression is 
26  Paton and Pertwee (1972).
27  See, for example, Lawrence and Gill (1975).
28  See, for example, Korte and Sieper (1960).The Medicalization of Cannabis
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that we really did it out of our own resources. In fact we were quite pleased as it 
made us, without being chauvinistic about it, independent of the NIH, which 
was then circulating samples of THC. I must confess, I hadn’t realized that 
Raphael Mechoulam was so generous – I wondered actually where the NIH got 
their material from; I hadn’t realized their THC came from your lab, Raphael.
Tansey: Can I ask Professor Pertwee to carry on the story about the pharmacology 
with Bill Paton. 
Professor Roger Pertwee: I entered the cannabinoid field in the 1960s, which 
was, as we’ve already heard, a time when tincture of cannabis was actually still 
a medicine. My wife, Teresa, whom I first met around that time, told me that 
it was in fact still being used. She was a nurse and used to give it to hospital 
patients. So it was still being used as a medicine in the early 1960s. It was a time 
when we thought, quite rightly as it turned out, that THC was probably the 
main psychoactive constituent of cannabis, but we knew very little else about the 
pharmacology of cannabis. The structure of THC, thanks to Raphi Mechoulam, 
had just been elucidated, and indeed, it had also just been synthesized by him 
– a very important step, as it meant that we didn’t have to rely solely on plant-
derived cannabinoids. That said, it was very difficult initially, although possible 
eventually, to get hold of synthetic THC. 
At that time, recreational cannabis use had become a major issue and certainly 
in the US, a lot of research was focusing on the harmful effects of cannabis and 
much less on its potential medicinal uses. In fact, in the early 1970s, tincture 
of cannabis was banned.
29 It was no longer a licenced medicine. The main 
interest then was in asking why cannabis is bad for you and why it is taken 
recreationally. A lot of the early pharmacology was descriptive, because so little 
was known and you could go in any direction you liked and there would be 
new stuff to learn about what THC and cannabis were doing. There was a lot 
of interest then in establishing whether THC is indeed the main psychoactive 
constituent of cannabis and hence in comparing the two pharmacologically. 
Tincture of cannabis remained very important to me because, before it was 
banned as a medicine, it was our main source of cannabinoids. Edward Gill 
29  Tincture of cannabis received a ‘licence of right’ under the 1968 Medicines Act that enabled doctors 
to prescribe it. However, this was not renewed when the 1971 Misuse of Drugs Act repealed the earlier 
Dangerous Drugs Act (1965). The regulations listed cannabis, cannabis resin, cannabinol and its derivatives 
in Schedule 4, which prohibited medical use altogether. See www.publications.parliament.uk/pa/ld199798/
ldselect/ldsctech/151/15103.htm (visited 18 January 2010).The Medicalization of Cannabis
14
has already mentioned the countercurrent chromatography machine.
30 It was a 
vast machine, that would have stretched from about where I’m sitting now to 
that window [c. six metres], chuntering away in his lab. At one particular point, 
there would be the THC you could run off, and a bit further down, cannabidiol 
(CBD). Without it we couldn’t have done any of our early cannabinoid research.
31 
I began my research on cannabinoids in 1968. I was completing my DPhil at the 
time at Oxford; this was on anaesthetics, which was probably one of the reasons 
I was asked to work on cannabinoids. Thus Bill Paton, and I think Edward Gill 
as well, believed very strongly that because cannabinoids are very lipid-soluble 
(lipophilic) molecules, they produce their effects by perturbing membrane lipids in 
the same way that some general anaesthetics are thought to do, they used the term 
‘partial anaesthetic’ for cannabinoids because these compounds cannot produce 
complete anaesthesia, possibly because they are too water-insoluble, but that’s 
another story. My own contribution was to develop a good bioassay for cannabis 
and THC and for this I decided to exploit their cataleptic effect. Cannabis and 
THC produce a very marked cataleptic effect in rodents. Treated animals wander 
around normally, or so it would seem, for part of the time, and then suddenly go 
off into a trance-like state, getting what looks like a total high. They then seem 
to recover before going off into another trance-like state.
32 Very strange. I’d read a 
paper by a chap called Sigmund Loewe, who in the 1940s produced a large tome 
on cannabinoids.
33 One of the things he mentioned was that if you place a mouse 
across the rim of a beaker, when you’ve given it some cannabis it goes off into a 
strange trance-like state for a short period of time and then recovers and so on. 
So I developed my assay by exchanging the rim of the beaker for a wire ring and 
called it the ring test, and we published a paper on this in 1972.
34 That test was 
included later by Billy Martin’s group as one of a set of four tetrad assays.
35 
This takes us forward a bit, as it was a time when the receptors had just been 
discovered. It was a challenging time because there were no antagonists around 
30  See discussion on page 11.
31  See note 24.
32  For a demonstration of this effect see Horizon: Cannabis: the evil weed? (dir. Andrea Gillings, broadcast 
on BBC2 TV, 2 February 2009).
33  Loewe (1944, 1946, 1950). 
34  Pertwee (1972).
35  The tetrad assays measured tail-flick response, rectal temperature, catalepsy and motor activity in mice 
after administration of cannabinoid. See Smith et al. (1994).The Medicalization of Cannabis
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and you needed to have some way of telling when you were looking for new 
compounds whether they were acting like cannabis or THC or not. Martin 
picked four assays, the idea being that if the compound was active in all four 
assays  then  it  was  probably  a  cannabinoid-like  compound  with  a  similar 
pharmacology to THC. At that time there seemed to be no other kinds of 
compound that behaved like THC in all four assays, though a few compounds 
that are active in the tetrad but do not have a THC-like mode of action have been 
discovered more recently. Another assay that forms part of the tetrad exploits 
the hypothermic effect of THC. We had studied the effects of THC and other 
molecules on body temperature, but I won’t bore you with the details. Suffice 
to say that we obtained very good evidence that whereas fever up-regulates your 
set point, THC in mice seems to lower the set point, such that although they 
continue to thermoregulate they do this to maintain a subnormal temperature. 
This is something we might want to come back to in the future, because maybe 
endogenous cannabinoids have got something to do with hibernation.
As well as working with THC, we also did a bit of research with CBD and 
showed that it can target P450 enzymes. This research was done at a time before 
too much was known about these enzymes, but we were able to show that, 
for example, CBD had a very marked inhibitory effect on the metabolism of 
barbiturates in the liver.
36 It’s really quite an effective inhibitor of P450 enzymes. 
Time and again, new techniques and ideas emerging in the general scientific 
field  have  influenced  the  direction  that  the  cannabinoid  field  has  taken. 
Research supposedly should be hypothesis-driven, but it is, in reality, technique-
dependent. This happened in the early 1970s with P450 enzymes, at a time 
when nearly every other pharmacological paper seemed to be on these enzymes.
Another cannabinoid we looked at was the one that has already been mentioned 
by Edward Gill, the propyl analogue of THC, and that was, again, in the late 
1960s. We found that it did in fact behave rather like THC, it was just a bit 
less potent; end of story at that time, because we were really focusing on THC.
37 
But much more recently, in 2004, Geoffrey Guy nagged me into having another 
look at propyl THC, also known as tetrahydrocannabivarin (THCV), and we 
got some really interesting findings with it. These showed that although it does 
indeed behave the way we had found it to do back in the 1960s, at much 
lower concentrations it’s actually an antagonist: it actually blocks cannabinoid 
36  Paton and Pertwee (1972).
37  See Gill et al. (1970) and page 11. The Medicalization of Cannabis
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receptors.
38 So, as I was saying to them earlier, I’m surprised that these two guys 
(Raphael Mechoulam and Edward Gill) are sitting next to each other and not 
quarrelling, because we have the discoverer of the agonist (THC) sitting next to 
the discoverer of the antagonist (THCV). Both THC and THCV are present in 
the same plant material and in the tincture, of course, in roughly equal amounts, 
so I’m not quite sure exactly what the tincture was doing, since it had both the 
agonist and the antagonist present. One thing I learned from meetings at the 
Royal Pharmaceutical Society, something I hadn’t really appreciated before, is 
that cannabis does not itself contain much THC. It contains the acid of THC, 
I was told, though Raphi Mechoulam doesn’t agree with this. I was told that it 
is when cannabis is heated that a lot of the acid gets converted to THC. There 
may be some THC there, but the amounts increase when you heat it or burn 
it. Moving on, all of the obvious research had been done with cannabinoids by 
the early 1980s and things went into the doldrums for a while, a situation that 
changed dramatically with the discovery that there are cannabinoid receptors.
Tansey: So you’re now in Aberdeen? Just for the record. 
Pertwee: I’m now in Aberdeen, yes, I moved there in 1974. I actually took over 
from a chap called John Hughes, who gave up his lectureship in order to work in 
Aberdeen on compounds that came to be called the enkephalins (endorphins). It 
was shortly afterwards, of course, that he and Hans Kosterlitz did indeed discover 
the enkephalins.
39 What is quite weird is that at that time when we got that 
fantastic compound sent to us by Raphi Mechoulam, which we subsequently 
called anandamide, I was based in the actual lab in which Kosterlitz and Hughes 
had worked on enkephalins, as they had by then moved into a different lab. 
This was down in Marischal College in Aberdeen. It signalled the end of the 
time when cannabinoid research was in the doldrums as indicated by the lack of 
funding for it available at that time. I had, by the way, been funded at Oxford by 
the MRC as I had a postdoctoral MRC position there. 
People  like  Billy  Martin  in  the  US  had,  to  some  extent,  moved  into 
amphetamines, cocaine and that sort of thing, away from cannabinoids.
40 I 
think the whole thing was saved by big pharma in the form of Pfizer, who 
came  up  with  this  very  interesting  compound,  CP55940  and  its  tritiated 
38  Thomas et al. (2005).
39  For discussion of Hughes and Kosterlitz’s work on endogenous opiates, see Tansey and Christie (eds) 
(1997a).
40  See, for example, Dewey et al. (1982). See also Klein et al. (2008).The Medicalization of Cannabis
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version. One big challenge then had been to explore the possibility that there 
might be cannabinoid receptors by seeking out specific binding sites for THC, 
something that Billy Martin’s group had tried to do. THC is too lipophilic 
and doesn’t have a strong enough affinity for the cannabinoid receptors, so 
you get nearly all non-specific binding – very little specific binding, and so 
that approach was not successful. But CP55940 has much higher affinity for 
what turned out to be the CB1 receptor and also the CB2 receptor, and it 
was possible to actually do decent binding studies with tritiated CP55940. 
Allyn Howlett in the US was the first person to do that, along with a chap 
called Bill Devane, who was her PhD student at the time.
41 They were able to 
demonstrate these high-affinity binding sites and that led to the discovery of 
the receptors. They also carried out signalling studies, as this was a time when 
a huge amount of research on G protein-coupled receptors was going on. G 
protein research was a big thing in the 1980s and Allyn Howlett was an expert 
on that. She was able to show that THC and CP55940 were probably acting 
on something that relied on G protein-mediated signalling. 
Another  important  technique  developed  around  that  time  was  receptor 
cloning, and that happened for the CB1 receptor in 1990, in Tom Bonner’s 
lab at the National Institute of Mental Health (NIMH), Bethesda, MD. In 
his lab, Lisa Matsuda had been able to clone a new receptor, but had no idea 
what she’d cloned. I don’t know the complete story, someone else here may 
know, but I think one day she or Tom Bonner saw where another NIMH 
scientist, Miles Herkenham, had found the CB1 receptor binding sites to be 
located in the brain. The cloned receptor was located in the same brain areas, 
so they put two and two together and came up with the idea that they must 
have cloned a CB1 receptor and went on to demonstrate that. Their paper was 
published in 1990 and after that, the field really exploded as far as the science 
was concerned.
42 
In parallel with all of this, of course, and we’ll probably discuss it later, there 
were  clinical  trials  happening  that  resulted  in  two  cannabinoids  becoming 
licenced medicines. One was a compound called Nabilone
®, developed by Eli 
Lilly, which entered the clinic in 1981 as an antiemetic.
43 The other was THC 
itself; a lot of people don’t know that synthetic THC was and still is a medicine 
41  See, for example, Devane et al. (1986, 1988); Howlett et al. (1990). 
42  Matsuda et al. (1990, 1992).
43  See, for example, Einhorn (1982).The Medicalization of Cannabis
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called Marinol (dronabinol). It entered the clinic in 1985 as an antiemetic and 
again in 1991 as an appetite stimulant, particularly for AIDS patients.
44 
With the discovery of the CB1 receptor the field really exploded. Particularly 
important was the discovery of endogenous cannabinoids; Raphi Mechoulam 
asking the fantastic question: ‘If there are receptors, are there also endogenous 
ligands for these receptors?’ And anandamide was discovered and was followed 
two years later by 2-arachidonoyl glycerol.
45 The discovery of the CB1 receptor 
was of course followed by the discovery of the CB2 receptor.
46 The discovery 
of these two receptors led to the development of new synthetic ligands, by 
us and others, of compounds that targeted CB1 or CB2 receptors selectively 
as agonists and, very importantly, of antagonists, initially by Sanofi-Aventis, 
who came up with rimonabant (Acomplia
®), which although it has now left the 
clinic – and that’s something we’ll come back to later maybe – it constituted 
a major advance as it made all the difference to us pharmacologists to have a 
selective antagonist around to work with.
47 Eventually, evidence emerged that 
the endocannabinoid system can be auto-protective in some instances and auto-
impairing in others; that it has its own pathology, in other words. Very often it is 
actually protective and again this is clinical, and something we may come back 
to later when we move onto clinical issues. A search also began for additional 
cannabinoid receptors and there is in fact a heated debate currently going on 
about whether the orphan G protein-coupled receptor, GPR55, is another 
cannabinoid receptor. Also, we have discovered an allosteric site on the CB1 
receptor, which means we can modulate that receptor allosterically, which could 
be very important, not only experimentally but also clinically.
48 
44  See note 9 and page 42. 
45  Devane et al. (1992); Mechoulam et al. (1995).
46  Professor Roger Pertwee wrote: ‘The CB2 receptor was first cloned by a British scientist, Sean Munro, in 
the UK. Munro et al. (1993).’ Note on draft transcript, 3 March 2010. 
47  See page 42. Professor Roger Pertwee wrote: ‘The discovery of the CB1 receptor also prompted us to 
develop in vitro bioassays for CB1 receptor ligands, for example, one that is performed with the mouse 
isolated vas deferens and played an important role in the discovery that anandamide is an endocannabinoid 
and  that  there  are  CB1  allosteric  sites,  a  second  bioassay  that  is  performed  with  myenteric  plexus-
longitudinal muscle tissue obtained from guinea pig small intestine, and a third that is performed with 
mouse isolated bladder. See Pertwee et al. (1992); Pertwee and Fernando (1996).’ Note on draft transcript, 
3 March 2010.
48  See, for example, Price et al. (2005).The Medicalization of Cannabis
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I’d like to end by pointing out one or two factors that facilitated all of this. 
One of them was actually that in the 1990s large numbers of press reports were 
published claiming that a lot of people were self-medicating with cannabis. 
That, I think, acted as a spur to people to reconsider the clinical potential of 
cannabinoids. A very important person in all that was Clare Hodges, who is 
here today, and we’ll come back to her contributions later, I’m sure.
49 I would 
just like to mention now that it was really thanks to her that we were able to 
carry out an anecdotal study in which we contacted patients who were self-
medicating with cannabis to find out why, and what the claimed benefits were. 
These were MS patients. We wrote this study up as a paper.
50 It was largely due 
to Clare that we were able to do this because she put us in contact with those 
patients. The interest in cannabis and MS at that time led David Baker, who is 
an expert in MS, to come into the field and explore at the preclinical level how 
cannabinoids might affect MS and what the mechanisms for this might be. 
David is here as well and I’m sure will say something later.
51 
Another facilitatory factor was the emergence of more democratically organized 
scientific meetings. We’d had a lot of meetings run by one or two people who 
always seemed to invite the same speakers, and it was kind of undemocratic. But 
then, in a timely way, in 1990 the International Cannabinoid Research Society 
was formed (initially as the International Cannabis Research Society) and that 
made a great difference.
52 This was a time, remember, before e-mail, when it was 
very difficult to communicate with one another efficiently. Now it’s so much 
easier, but there was a real need for a society like that, certainly before e-mail, 
and I think there still is. 
UK organizations were also very important. The British Medical Association 
(BMA) got very interested and finished up by producing a book.
53 The Royal 
Pharmaceutical  Society  (RPS)  was  also  very  important,  but  more  on  the 
49  See pages 20–1 and 61.
50  Consroe et al. (1997). See pages 55–6, below. 
51  See pages 51–3. 
52  See http://cannabinoidsociety.org/ (visited 19 January 2010).
53  British Medical Association (1997). Professor Roger Pertwee wrote: ‘The production of the book was 
prompted by a report the BMA had commissioned me to write (Pertwee (1997)). In December 1997, I also 
represented the BMA at a meeting at Westminster of the All-Party Parliamentary Committee on Multiple 
Sclerosis that had been convened to answer questions about the BMA report, Therapeutic Uses of Cannabis.’ 
E-mail to Ms Stefania Crowther, 8 March 2010.The Medicalization of Cannabis
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clinical side.
54 The House of Lords, again, was very important from the clinical 
side.
55 And then funding: for my own lab, the MRC initially at Oxford and 
then the Wellcome Trust, that funding was very important for us. I got two 
very good re-entry research fellows from that and one of them (Ruth Ross) is 
now a professor in Aberdeen and it’s great that she is still there.
56 The MRC 
funded a cannabinoid cooperative group in Aberdeen. That was good because 
it encouraged non-cannabinoid scientists in Aberdeen to begin working on 
cannabinoids. We also got UK funding from the Biotechnology and Biological 
Sciences Research Council and US funding from the NIH. 
Finally,  the  involvement  of  pharmaceutical  companies  was  very  important. 
They provided very useful pharmacological tools: CP55940 and rimonabant 
I’ve mentioned, but there was also SR144528, which is a very important CB2 
selective antagonist, again a Sanofi-Aventis compound. It was possible for some 
of us to become consultants for one or other of these companies and that meant 
we had access to interesting novel compounds and it was really as a result of 
getting compounds from Organon,
57 for whom I was a consultant a few years 
ago, that we discovered the CB1 allosteric site. When I got their compounds we 
didn’t realize that they were allosteric modulators, but from the experiments we 
did, it became clear that they were, and that led us on to discover this allosteric 
site on the CB1 receptor, which I think could be really important therapeutically. 
Tansey: You’ve raised a lot of questions there. Dr Hodges, do you want to come 
in at this point? 
dr clare hodges: This made me think about the great increase in interest, since 
the real social change, and realize how much difference it made to scientists that 
54  Professor Roger Pertwee wrote: ‘In April 1998, I was invited to the House of Commons to present 
scientific and clinical evidence about the therapeutic potential of cannabinoids to the Parliamentary and 
Scientific Committee. In May 1998, I was invited to the House of Lords to give evidence to its sub-
committee on cannabis, a transcript of which was published as House of Lords, Select Committee on 
Science and Technology (1998): 64–83, 280. I also contributed to a written memorandum by the Royal 
Society and the Academy of Medical Sciences that is published in the same report (pages 293–8, 300–1).’ 
E-mail to Ms Stefania Crowther, 8 March 2010. See page 35, below. 
55  See pages 38–9.
56  Professor Roger Pertwee wrote: ‘Ruth Ross is professor in the school of medical sciences, Institute of 
Medical Sciences, University of Aberdeen. See, for example, Ross (2009).’ E-mail to Ms Stefania Crowther, 
8 March 2010.
57  Organon International became part of Schering-Plough Corporation, Kenilworth, NJ, (Merck & Co. 
Inc., Whitehouse Station, NJ, from 2009) in 2007.The Medicalization of Cannabis
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so many patients used cannabis. As Dr Pertwee said, I helped him to interview 
by post all those people who were using it, and that changed everything.
58 Then 
politicians, doctors and everyone started taking it very seriously, because so 
many people were using it. They realized it was worth finding out what was 
going on and that was when research started happening. 
Tansey: It was very important. We will come back to the question of patients 
and activism towards the end of the meeting.
Mechoulam: Let me go back a bit, as I didn’t mention any pharmacology. The 
basic technique of identifying an active compound in a mixture is to have 
feedback from a biological test of some kind. When we started identifying the 
components in the cannabis mixture, we had to use feedback from monkeys. 
At that time a good friend and colleague, Dr Habib Edery, who was the head 
of  pharmacology  at  the  Biological  Research  Institute,  not  far  away  from 
the Weizmann Institute, had a colony of monkeys and we would give him 
extracts, chromatographic fractions or purified compounds and when we got 
the results back we could put aside the inactive fractions.
59 What was the 
activity? Edery found that half a milligram of THC given to a small rhesus 
monkey would sedate it.
60 This was the first pharmacological test that we used. 
Then we had to find out whether the other compounds were active; they were 
not. But we also had to find out whether the other compounds had some 
kind of synergistic activity when added to THC. So we got all the inactive 
compounds we had and put them together with THC and looked for any 
changes in activity. Habib Edery found that there was no change.
61 So we 
could say that THC is the only active compound. This was the pharmacology 
we used at that time; the less expensive tests in mice were not available and we 
didn’t have dogs to test for dog ataxia, which was the standard technique for 
evaluating cannabinoids.
Tansey: Could you put a date on that for us, please? 
58  See pages 55–6.
59  Professor Raphael Mechoulam wrote: ‘Dr Habib Edery was born in Argentina, I believe, and came to 
Israel in the 1950s. He was head of the pharmacology department in the Biological Institute, Nes Ziona, 
Israel. In the late 1980s he had a stroke. Feeling that he was losing his memory, he became depressed and 
committed suicide.’ E-mail to Ms Stefania Crowther, 9 March 2010. 
60  Edery et al. (1971).
61  Mechoulam et al. (1970). The Medicalization of Cannabis
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Mechoulam: We started collaborating with Habib Edery in the early 1960s 
–  1963  or  1964.  We  later  published  a  paper  in  Science  showing  that  the 
other cannabis components were not psychoactive and did not synergize the 
psychoactivity  of THC  and  therefore,  from  that  viewpoint,  they  were  not 
interesting.
62 They had, however, many other pharmacological activities, which 
were published later on.
A few words on the metabolism of THC: strangely enough, there were four 
papers,  including  ours,  published  essentially  simultaneously,  saying  more 
or less the same thing: in the initial step a hydroxyl group goes to the seven 
position (today it’s called the 11 position).
63 Thus, THC first forms an active 
component, which has a lot to do with the activity in the body, and then it is 
converted into an acid, a cannabinoid acid, which we discovered together with 
a Swedish group, which is not active, and stays in the lipids in the body for 
many weeks.
64 Therefore, today, if you want to find out whether somebody is 
using cannabis, you can analyse the urine and find the cannabinoid acid, THC 
acid, almost six or eight weeks after their last use of cannabis. All this goes 
back to the 1960s and early 1970s. Would you like me to say something about 
anandamide at this point?
Tansey: Yes, please do.
Mechoulam: As was mentioned earlier, Allyn Howlett identified an active site, 
a receptor, in the 1980s. The reason why a receptor was found only about 20 
years after THC was discovered was that there was a mix-up in the literature, 
partly because the Oxford group had thought, and rightly so, that it may act as 
a partial anaesthetic. Let me explain. When there is a compound that exists in 
two mirror images, enantiomers, normally only one will be active in the body, 
because the active sites, the receptors, DNA or enzymes, are all asymmetric. 
Therefore,  only  one  enantiomer  should  be  active.  If  both  are  active  then 
probably the activity is not due to a receptor or an enzyme or DNA or other 
body constituents, but is ‘unspecific’. It was shown that with synthetic THC, 
both the (-) form and the (+) form were active. Therefore, THC was probably 
not acting on a receptor. Well, it turned out that people were synthesizing THC, 
the (+) form, from commercial starting material, which is not very pure and 
62  See note 61.
63  Burstein et al. (1970); Wall et al. (1970); Nilsson et al. (1970); Foltz et al. (1970).
64  Professor Raphael Mechoulam wrote: ‘Led by Stig Agurell.’ Note on draft transcript, 9 March 2010. See 
Nilsson et al. (1970).The Medicalization of Cannabis
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contained some of the (-) form. Therefore, at the end, rather than having pure 
(+) THC, they had (+) THC with some (-) THC and therefore some activity 
was noted. Due to that, well I wouldn’t say mistake, but just an unfortunate 
situation, the existence of receptors was not investigated. When we and others 
published that there is actually a complete separation of activity between the 
two enantiomeric forms, it became almost certain that THC acts on some body 
molecule, enzyme, receptor or DNA. Allyn Howlett took up the challenge, 
went ahead and found the main CB1 receptor.
65 Later, a second group, in the 
UK, found the CB2 receptor.
66 
Obviously, receptors are not around to be activated by plants; that is not the 
way nature works. So we went ahead looking for something in the mammalian 
body that would act on the receptor. There were several groups looking for 
compounds of this type, and most of the groups that were looking for them and 
actually published something on such compounds were looking at proteins, 
because most of the active compounds that stimulate receptors are proteins or 
peptides, small peptides. But in this case we went the other way; as THC is 
lipid-soluble, we thought that the active compound in the body would also be a 
lipid-soluble compound. The main lipid-soluble compounds, the main lipids, 
are fatty-acid derivatives. So, we went ahead looking for lipid-soluble materials 
and indeed the first compound we identified, which we called anandamide, 
was a fatty-acid derivative. The isolation and identification involved quite a 
lot of work. Bill Devane, who had been a student of Allyn Howlett, joined 
my  group  in  1991  to  study  chemistry.  As  he  knew  the  techniques  with 
cannabis receptors, I thought it would be a nice project for him to look for 
the  endogenous  cannabinoid.  We  looked  at  pig  brains  because,  strangely 
enough, pig biochemistry is close to human biochemistry and we were, of 
course, interested in human biochemistry.
67 We soon found that there was a 
problem because the endogenous cannabinoid was not very stable. We had to 
do a lot of chromatography, and while the purification went ahead, the activity 
(namely the binding to the receptor) went down, because the compound was 
deteriorating. We now know that it was being oxidized, as there are lots of 
labile double bonds in the molecule. It took us about two years to obtain an 
almost pure compound, which, with then modern techniques – now about 18 
65  Devane et al. (1988). See also note 41.
66  Munro et al. (1993).
67  Professor Raphael Mechoulam wrote: ‘At that time Lumir Hanuš from Czechoslovakia joined us.’ Note 
on draft transcript, 9 March 2010.The Medicalization of Cannabis
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years ago – we could identify its structure with very, very small amounts which 
we isolated from the pig brains. This is the way arachidonoyl ethanolamide, 
anandamide, was identified. Two or three years later, we identified a closely 
related active compound, arachidonoyl glycerol, 2-AG, an ester.
68 A few months 
after we published the identification of 2-AG, a Japanese group published the 
same compound.
69 They had been working on the same topic; we didn’t know 
that they were working on it, but they came to the same conclusion that we 
had already published. Since then, quite a few other components have been 
identified but anandamide and 2-AG still seem to be the main endogenous 
cannabinoids. There are also a lot of synthetic compounds with the same 
activities. There is also a huge family of endogenous compounds which belong 
to the same chemical group of fatty acid derivatives with either amino acids, 
ethanolamine or glycerol, known as endocannabinoid-like compounds. Most 
of them do not bind to the cannabinoid receptors but it seems that they are 
doing a lot of interesting things in the body. As a matter of fact, one can see 
some of these compounds involved in almost all physiological systems, and I 
assume that work on them will be a major thing in the future.
Gill: I thought it might be interesting, before we move into the rather later 
clinical phase, to go back to a point that Roger Pertwee made about the flurry 
of activity that took place in the late 1960s to the mid-1970s, which you 
might call the first wave of proper scientific work. I think it worth emphasizing 
that a lot of the interest over that period was in trying to establish whether 
cannabis was harmful. And, although, as mentioned, there were references to 
clinical use dotted around in the literature, I think the main thrust of the work 
that was being done then was trying to establish whether there was a clear-
cut case for de-criminalizing cannabis. It’s clearly difficult to prove a negative, 
i.e. to demonstrate that THC was not harmful, and therefore one rather got 
the feeling that a lot of the work that was being financed was really simply to 
establish whether you could clearly demonstrate a harmful effect. If that was 
the case then that would really take care of the legislative problem; there’s no 
question of getting involved in all the other side issues; the stuff was dangerous 
so it ought to be controlled. There was a lot of work that went on, I think, in the 
early 1970s, of people trying to detect all sorts of mutagenic effects. There were 
arguments about whether or not you should use solutions of pure THC; the 
fact that it was smoked and inhaled meant that there were people puffing smoke 
68  Mechoulam et al. (1995). 
69  Sugiura et al. (1995). The Medicalization of Cannabis
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at Petri dishes full of bacteria and whatever.
70 It was interesting; I don’t think the 
NIH was in itself particularly biased one way or the other about THC toxicity. 
There was a lovely woman, Monique Braude, who was, I think, then the main 
coordinator from the NIH for THC research and she was the main source of 
samples of pure THC. She was touring around Europe trying to identify groups 
that were working on THC.
71 
As Roger has reminded me, there was a sort of asymmetry of judgement, and there 
was a character called Gabriel Nahas who was totally persuaded that cannabis 
was very harmful; he was a great one for organizing conferences of like-minded 
workers, to reinforce the message.
72 In evaluating all that quasi-toxicological work 
that was being done in the 1970s, there was a sort of asymmetry of judgement. A 
lot of people came at it with the preconceived view that it was dangerous and so 
you would find reviews that were written that very much emphasized the negative 
findings. You would then find another review that assembled an equal number of 
papers to show that the alleged harmful effects couldn’t be reproduced. It was a 
very tangled field. One rather got the impression, or rather I got the impression, 
that by the time we got into the middle of the 1970s, the effects were at best 
marginal, second-order; there was no overwhelming case that could be made 
against cannabis on the grounds of toxicity. It was at that point that the subject 
lost momentum. If it hadn’t been for the discovery of the receptor in the second 
wave, I think it would have gone like alcohol as a research topic, it would have 
simply have died; there would be odd little clusters of workers around the world 
pottering around, and nothing would have happened to it. But, looking at the 
reviews and the comments that were being made at that time, it all struck me 
that there was, as I say, this asymmetry in the judgement of a lot of it. I have 
70  See, for example, Nahas (1973, 1976); Paton and Pertwee (1973).
71  Dr Monique Braude (1925–2010) received a diploma from the Institute of Pharmacy, University of 
Paris and a doctorate in pharmacology from Ohio State University in 1955. She worked at the National 
Institute on Drug Abuse, National Institutes of Health, Bethesda, MD until 1987, where she became head 
of preclinical research in 1974 and directed a programme to determine the preclinical biological effects of 
marijuana and other drugs of abuse. See, for example, Rosenkrantz et al. (1972). Dr Edward Gill wrote: 
‘Because we (the Oxford group) were self-funded and had our own source of THC, we did not have very 
close contacts with Monique Braude and the NIH. She came to visit us a couple of times and we talked at 
conferences, but our relationship was quite informal.... As far as her tours round Europe were concerned, I 
think they were mainly to find out what was being done (there was an active group in Holland, for instance) 
and, possibly, to provide support.’ E-mail to Ms Stefania Crowther, 1 March 2010.
72  Professor Gabriel Nahas is emeritus professor of anaesthesiology and medicine at Columbia University, 
New York, NY. See, for example, Nahas (1973, 1976).The Medicalization of Cannabis
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to say that I think Bill Paton himself was slightly asymmetric in his view of the 
literature. He applied all his very considerable critical skills to a lot of what you 
might call the positive evidence (i.e. that it was not harmful) and was much more 
tolerant about the negative evidence.
73
dr Vincenzo di Marzo: I would like, if I may, to go back to the importance of 
the discovery of the endocannabinoids, because some people view this issue as 
possibly separate from the medicalization of cannabis. In fact, we got, and were 
getting, many hints from knowing how the endocannabinoids are made and 
how they are regulated and how to use the plant cannabinoids. The discovery of 
the endocannabinoids, which we owe, again, to Professor Mechoulam, in fact, in 
addition to what Roger Pertwee just mentioned, I think, opened new avenues of 
research. One with which we were particularly involved was to try to understand, 
through the physiology of mammals and eventually of human beings, how 
the  levels  of  these  compounds  could  be  regulated  during  physiological  and 
pathological conditions. By developing some analytical techniques to isolate, 
measure and quantify the endocannabinoids in physiological and pathological 
conditions, in our lab and in many others, we and others could understand 
how these endogenous compounds, which we named endocannabinoids, could 
behave as prohomeostatic protective endogenous mediators and therefore tell us 
where to use THC to activate CB1 and CB2 receptors and in what pathological 
conditions.  On  the  other  hand,  it  also  allowed  us  to  understand  that  this 
system can be regulated, so it can alleviate some symptoms of disorders, while 
exacerbating others. The typical examples of that are obesity, hyperphagia and 
metabolic disorders; that is, conditions in which we should use antagonists of 
cannabinoid receptors like rimonabant, of which THCV is the plant counterpart. 
More recently, the third way in which the endocannabinoids can help us in using 
plant cannabinoids therapeutically is by understanding how the endocannabinoids 
are made, to identify the enzymes that make and degrade the endocannabinoids, 
some of which can be targeted by phytocannabinoids, plant cannabinoids and, I 
think, mostly of cannabidiol, for which there are many, many potential targets. 
Very interesting therapeutically; a potentially interesting plant cannabinoid for 
which there is still no single molecular target receptor. One discovery is that 
endocannabinoids,  anandamide  in  particular,  are  quite  promiscuous  –  they 
bind to other receptors, not just to the so-called cannabinoid receptors, but to 
other proteins, completely different from CB1 and CB2, for example – and 
73  See Paton and Pertwee (1973). Sir William Paton’s papers are held in archives and manuscripts, Wellcome 
Library, London, at PP/WDP.The Medicalization of Cannabis
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the serendipitous finding that some plant cannabinoids do the same – they also 
interact with these other, non-canonical cannabinoid receptors. So, I think there 
are at least three other ways through which the discovery of the endocannabinoids 
can help us decide when and for what pathologies we can use plant cannabinoids. 
Professor  John  Galloway:  Could someone clarify whether the endogenous 
opioids  were  already  established  by  the  time  you  started  looking  for  the 
endogenous cannabinoids? 
Pertwee: Yes, the enkephalins were discovered in the 1970s and the first paper 
on anandamide was published in 1992.
74
Galloway: In that case, I wanted to make a comment, because Hans Kosterlitz 
told me that he gave the credit for the idea of the endogenous opioids to 
Thomas Mann in The Magic Mountain.
75 I wonder whether anyone else had 
ever come across that suggestion? There is a quote in The Magic Mountain: ‘A 
sort of poisoning, an auto-infection of the organisms, so Dr Krokowski said; it 
was caused by the disintegration of a substance, of the nature of which we were 
still ignorant, but which was present everywhere in the body; and the products 
of this disintegration operated like an intoxicant upon the nerve-centres of the 
spinal cord, with an effect similar to that of certain poisons, such as morphia, 
or cocaine, when introduced in the usual way from outside’, which he reckoned 
was a clear indication that there were endogenous opioids. I once wrote a short 
article for the New Scientist in which I pointed that out.
76 I thought people 
might be interested to know that.
Tansey: That’s really moving us into the realm of medical humanities. 
Pertwee: One race we did win was to clone a receptor: the CB1 receptor was 
cloned in 1990, a year or two before any of the opioid receptors.
77 
Tansey:  Thank you very much for all of your very helpful and interesting 
comments  about  the  basic  science  that  underpins  the  medicalization  of 
cannabis. I’m now going to hand over to Virginia Berridge, who is going to chair 
the session on industry and regulation, which leads on very nicely from what   
Dr Di Marzo has just been saying about therapeutic implications. 
74  Devane et al. (1992). See also Tansey and Christie (eds) (1997a).
75  Mann (1960): 188.
76  Galloway (1986).
77  See page 17; Evans et al. (1992). The Medicalization of Cannabis
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berridge: I wonder, talking about the debates that went on in the 1970s, which 
Dr Gill referred to,
78 whether Griffith Edwards has any comment to make from 
his involvement with expert committees in that period. 
Professor Griffith edwards: I feel like a child among my elders listening to such 
fascinating and distinguished accounts of laboratory science, so please know 
that I am aware I have no standing there. I am a witness to history in that I 
knew Bill Paton very well, a man I was very fond of and who assisted me in 
various ways. From the early 1970s, I was involved with a British body called 
the Home Office’s Advisory Council on the Misuse of Drugs (ACMD), which 
is a statutory organization; its existence is embedded in the Misuse of Drugs 
Act of 1971, so even when Mrs Thatcher was trying to get rid of QUANGOs 
(quasi-autonomous  non-governmental  organizations),  she  couldn’t  touch  it. 
Its powerful technical advisor over many years was the pharmacologist Jamie 
Graham.
79 And if you talk about asymmetry, Jamie Graham was asymmetry 
personified: he believed that cannabis should be legalized. Incidentally, I don’t 
think you can get that out of Barbara Wootton: I think she was more cautious; 
she was a liberal-minded person, but I don’t think she recommended outright 
legalization. The ACMD was not a cutting-edge organization for its efficiency 
and it could take six years for any working party to report. It got bogged down 
with cannabis and I actually made the suggestion that we needed a working 
group specially to look at the damage questions. I persuaded the council to ask 
Bill Paton to join us because, for some extraordinary reason, he was never a 
member of that council. We produced a report, which I believe was objective, 
on the possible harms with many open questions.
80 My understanding of the 
temper of the times was that we felt that we needed to know more about 
damages and dangers and that open-mindedness should be the order of the day. 
The medical profession had made an absolute hash of it by underestimating 
the dangers of barbiturates; we got it wrong with amphetamines; later, we were 
going to get it wrong with benzodiazepines and there was therefore a case for 
caution. We also felt that the epidemiological science on danger was pretty 
primitive because one likes to look at a dose–response relationship, as one can 
so easily do with tobacco, but you never knew the strength of the cannabis 
78  See discussion on page 24. 
79  Dr James Graham was professor of pharmacology at the University of Wales, Cardiff from 1950 to 1989. 
See www.nedprod.com/cannabis/essays/wraltnet.txt (visited 11 June 2009).
80  Home Office, Advisory Council on the Misuse of Drugs (1982) includes a section by Sir William Paton 
on ‘Cannabis and the cardiovascular system’, page 9. The Medicalization of Cannabis
29
being smoked and you never knew how many people shared a reefer; you were 
floundering around in the dark. I don’t think there was ever any feeling in the 
official mind that one was out to diabolize cannabis, or grubbing around to find 
damaging implications, but one did need to know more, and one didn’t know 
nearly enough. The debate did, at times, become very clouded. One couldn’t 
live in the world of pure reason that one would like to inhabit, when there 
were people signing a petition in The Times in 1967 demanding legalization.
81 
That was a tremendous act of very clever publicity, but it did rather cloud and 
popularize the background to the debate. Later on, when the Independent on 
Sunday, quite scandalously, had marches with people suffering from MS at the 
front of the parade, science and passion were much confused.
82 So, I think, the 
official mind-set would have been – who dares speak for the official mind? It’s 
a very personal reading of it – that one should be very willing to determine 
the therapeutic value of THC, even if it were dangerous, because we knew we 
needed better drugs for pain relief. The pain specialists really made us feel a 
bit ashamed if we had thought that morphine and heroin were enough; they 
weren’t. We needed better drugs. If there were drugs that were effective, but still 
carried some dependence risk, or some toxicological danger in high doses, one 
should determine that by controlled trial. I always naively hoped to inhabit the 
world of pure reason and pure science, but the world, of course, isn’t like that. 
With drugs we live within a context, often of passion, muddle, overstatement 
and betrayal of logic. I’m sure it’s always going to be like that.
81  Soma Research Association, led by Steve Abrams, placed an advertisement in The Times on 24 July 1967 
that stated: ‘The law against marijuana is immoral in principle and unworkable in practice’, signed by   
65 prominent people, including Paul McCartney (later Sir Paul) and Brian Epstein, who Adams credits with 
having provided the finance. See Abrams (1997); Grunberg and Harris (2005): 97–8. Bipartisan legislation 
to decriminalize cannabis was reintroduced by Reginald Maudling MP and became law as the Misuse of 
Drugs Act 1971, with the maximum penalty for possession of cannabis on summary conviction halved to 
six months, and received the Royal Assent in 1973. 
82  Verity Lesson, a 20-year-old MS patient, was placed in her wheelchair smoking cannabis at the front 
of a march to Hyde Park, London, on 18 March 1998, led by Labour MP Paul Flynn and reportedly 
attended by 16 000 people aiming to pressurize the government to downgrade cannabis from class B to 
C. See Ball (1998); http://news.bbc.co.uk/1/hi/uk/70856.stm (visited 15 February 2010). The march 
was part of the legalization campaign initiated by Rosie Boycott, editor of the Independent on Sunday in 
September 1997. On 11 December 1997 the newspaper held a conference on cannabis: Cannabis: Should 
it be decriminalised? Independent On Sunday debate, Queen Elizabeth Conference Centre, Westminster, 
London; see Wynne-Jones (1997); www.ukcia.org/library/11dec97debate.php (visited 15 February 2010). 
Boycott’s campaign lasted for ten years before the Independent printed a retraction and an apology to the 
public. See Anon (2007); Owen (2007).The Medicalization of Cannabis
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berridge: I think we’ll move now onto the industry interest, and we’ve already 
heard about Pfizer and Eli Lilly, but latterly it’s been GW Pharmaceuticals, 
which has taken cannabis up as a medicine, so I think Geoffrey Guy is going to 
start the ball rolling for us on this. 
dr  Geoffrey  Guy:  To  understand  why  we  set  off  with  cannabis  extracts, 
I think one has to understand a little bit about the regulation of medicines. 
Since the Second World War, and certainly since the 1960s, the Dunlop report 
and afterwards, medicines regulation pertained to single chemical entities.
83 
Nearly all the regulations in the last 25 years relate to those and, therefore, the 
methods of preparation, manufacture, testing, quality control, consistency, in 
all the regulations, relates to single chemicals. So, the prospect of developing 
a  medicine  that  contains  something  like  420  chemicals,  in  the  regulatory 
environment of the late 1980s and mid-1990s was considered to be pretty nigh 
impossible. There are a number of European pharmaceutical companies that 
have prospered greatly with their lead products being whole plant extracts, but 
have never been able to achieve regulatory approvals on the basis of quality, 
safety and efficacy – mainly to do with quality (which is consistency in the 
Anglo-Saxon axis of regulation). 
Why did we decide to buck the trend and try to be the first plant extract to 
be approved as a medicine in modern times: a whole extract? I think we have 
to go back to the early 1980s. I first started in the pharmaceutical industry 
in  1980.  My  responsibility  was  taking  new  chemical  entities  into  man;  I 
did about a dozen of those and that was interesting. The other part of the 
company I worked for made all of its money out of plant medicines and, in 
talking to the pharmacologists, it was very clear that when they looked for 
pharmacological activity using biological assays for plant medicines – these are 
a range of medicines that would be used in oncology, but also in other areas, as 
antidepressants, for prostatic hypertrophy, for example – they used laboratory 
models with which they then fractionated the extract looking for the active 
ingredient. This is something I’ve heard today: nearly everyone, except for 
Raphi Mechoulam, has used the phrase ‘the active ingredient’. What we found 
was that, to find the active ingredient, we would look for the fraction that had 
activity and we’d throw the other fraction away. We would keep fractionating 
down until we did our last fractionation and neither of them had activity. We 
put them back together again and they had activity. Then we took one of the 
fractions we’d thrown away earlier on and added it back to one of the ones that 
83  See, for example, Dunlop (1970). See also Tansey and Reynolds (eds) (1997b).The Medicalization of Cannabis
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didn’t work, and we had activity again. It was absolutely clear that in a lot of 
biological processes, not just at a single molecular basis, you had clear synergy 
within these plants. Then, of course, some of the fractions of the plant, when 
you added them back in, took away the activity of a fraction that you knew had 
activity. So, the notion that there could be agonists and antagonists in the same 
plant was well understood. This was at the Laboratoires Pierre Fabre, Castres, 
France, I hasten to add, back in the early 1980s. Being a young physician at that 
time I told the boss that all medicines should be made out of chemicals and that 
plants should be left behind; a few decades in church told me otherwise. 
So, moving forward, I think about another ten years, from the mid-1980s to 
1990s, I was asked to develop a medicine for atopic eczema, which was derived 
from a Chinese medicine with ten components. We carried out clinical trials with 
very, very nice results, but we had to present the consistency of these materials 
to the regulators. After they’d picked themselves up off the floor and stopped 
giggling about all of this, we tried to engage in a sensible discussion as to how, 
under the modern regulations, you could obtain approval for something that 
was not a single chemical entity. I have to say that the regulators were absolutely 
marvellous in this country, even to the extent that I think a couple of them took 
a trip to China. But trying to crack this nut with ten extracts of ten plants, none 
of which we were able to see where they were grown, was nearly impossible. The 
issue about developing a medicine from a plant is that you must have control of 
your starting material. Anybody who has worked with plant medicines knows 
that if they are dried in the open, they will be covered in bird droppings; if they 
are dried in kilns they will be full of heavy metals; if they were cut down late in 
the afternoon and left overnight then they will have fungal growth on them; and 
then they could be put on a dock and left in 90˚ F temperatures for six weeks 
and put on a ship for another eight weeks. When we opened boxes shipped 
from overseas, out would come mice, rats and spiders, and that was just the 
macroscopic stuff! 
The regulators were absolutely clear that they understood this: the materials 
were just like a biology project. What we decided to do was to build the quality 
into the extract – in my mind I wanted to have an extract because, you know, 
this medicine wasn’t broken so I wasn’t about to mend it – and it came very 
much from the mid-to-late 1990s, when the Government was very concerned 
about the MS patients being pushed up Whitehall as part of a campaign to have 
cannabis legalized.
84 When we looked at whether cannabis was a medicine in 
84  See note 82.The Medicalization of Cannabis
32
itself or contained elements that were therapeutic, I was quite convinced that 
we would need to have a material that was reflective of the material for which 
the data had been produced. Now, modern-day literature on the use of cannabis 
in medicine probably stems from 1839 with Sir William O’Shaughnessy, but 
Raphi Mechoulam would probably claim that it stems from the Assyrian tablets 
from about 2600 years ago, and Ethan Russo from the Chinese back in 2600 BC 
as well.
85 Here was the problem: most of the understanding of cannabis and its 
pharmacology in the 1980s and 1990s was, as you’ve heard, the pharmacology of 
THC. Now THC is the psychoactive product and for 50–100 years beforehand, 
people were growing cannabis for its psychoactive effects and there was a very 
simple biological assay for it: the cannabis that gave them a high, they kept and 
bred from, the ones that didn’t, they threw away. If you assay US marijuana 
you will find almost the entire cannabinoid composition is represented by 
THC. You can hardly measure any others: CBD is a fraction; THCV is just 
a little bit. By the way, I think the highest composition of THCV, the propyl 
derivative, you’ll find anywhere is about 20 per cent in Malaysian or south-east 
Asian or south-west African cannabis. So, we had a body of science describing 
the pharmacology of a plant that had been effectively grown for recreational use 
and it wasn’t surprising that all of the measures and the laboratory measures of 
its effect were for its recreational use. If you go back to the 1850s and if you go 
back 100, 200, 300 years, or even as recently as the 1920s or so, a high THC 
plant would not have been used in medicine. The entire body of literature that 
related to the use of cannabis in medicine was not related to the materials that 
were being grown in the 1980s and 1990s in North America. In the early to late 
1990s, most street cannabis in the UK that had, say, come from north Africa 
would have about a 50:50 ratio of CBD and THC. In nature, in wild types, 
CBD is the dominant cannabinoid, and Roger Pertwee is quite right: they’re in 
their acid form.
86 You find very, very little neutral THC or CBD in the plant. 
So, when we look at the medical literature, we’re looking at the literature of a 
plant that predominantly delivered CBD with some THC. The more recent 
science was science that related to THC. The very first e-mail that I sent to 
Raphi in 1997, I think, said, ‘Tell me about cannabinoid ratios’, because we 
understood from the work back in the 1980s that the ratios of the different 
85  O’Shaughnessy (1839a). See also Gorman (1984). The earliest known reference to cannabis is in 
Assyrian tablets of the seventh century BC. The Chinese emperor Shen Neng included cannabis tea in his 
pharmacopoeia of 2737 BC as a treatment for gout, malaria, beriberi, rheumatism and poor memory. See 
Jones (2006); Fankhauser (2002).
86  See page 16. The Medicalization of Cannabis
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constituents of the plant would determine its pharmacology. The ratios were 
determined by the genetics of the plant, how you grew it, how you harvested 
it and how you prepared it. And the Chinese know that: they’ve known that 
very, very well indeed. What we did was to go back in a detective role, to try to 
understand what the literature from the nineteenth century was referring to.
87 It 
isn’t modern-day, high-THC, recreational cannabis. 
That’s why I was determined in the very early studies, which we did with 
William (Willy) Notcutt – when was it Willy? 1998? 1999? All of the early 
studies initially looked at ratios with THC, CBD and the combination together, 
and this is coming up to the clinical side so I’ll step back a bit. So, when we 
determined that the medicine we wanted to develop and take to the regulators 
was one that had more than one cannabinoid in it, THC and CBD, and in fact 
we specified for at least seven minor cannabinoids, we then had to create a whole 
new set of tests, because the test that the regulators would normally recognize 
to standardize material simply didn’t count. We had to go back and decide how 
we would assay and how we would measure them.
88 As Raphi said, when you 
make these cannabinoids you get enantiomers of them, but, of course, nature 
is stereospecific: you’ll only ever find one enantiomer of a material in a plant. 
For example, one version of limonene makes the lemon taste like lemon, and 
the other version makes the orange taste like orange; it’s the same chemical, but 
they’re very, very different and the body would see those as very different.
89 
What we did was to set about growing very, very specific varieties of the plant, 
defined by their chemical components. We had one of the world’s top geneticists 
to help us do that: we do no splicing; it’s all breeding; it’s all Mendelian (and 
unlike Mendel, we don’t cheat).
90 We are able to virtually dial into the plant now, 
87  O’Shaughnessy (1839b).
88  Dr Geoffrey Guy wrote: ‘New methods of sample preparation, extraction and separation were devised. 
We produced our own range of ultra-pure internal standards with which to calibrate laboratory equipment. 
We  developed  a  complete  suite  of  analytical  methods  more  appropriate  to  measuring  multiple  plant 
constituents. Work undertaken to characterize each extract has now allowed us to identify and quantify 
approximately 90 per cent of the molecules present. Quality control and batch release specifications all had 
to be developed from scratch.’ Note on draft transcript, 23 March 2010.  
89  Limonene is a chiral molecule, (R)-(+) limonene smells of oranges while its enantiomer (S)-(-) limonene 
smells of lemons because the nasal receptors consist of chiral molecules that interact with the enantiomers 
differently. 
90  Sir Ronald Fisher suggested that Mendel’s results were ‘too good to be true’ in Fisher (1936). See also 
Mendel (1866); Pilpel (2007). The Medicalization of Cannabis
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to select what cannabinoid component we want. Once we had the cannabinoid 
composition in the plant, everything else in the manufacturing and pharmaceutical 
process to arrive at consistency stems from that. The plants are grown indoors, 
away from bird droppings, away from heavy metals; no chemicals are put on 
them whatsoever; we used biological methods for pest control. We are able to get 
quite remarkable consistency. The consistency of THC, for example, from a THC 
breeding variety when we make a primary extract, is of a higher purity than the 
standard the FDA would accept for synthetic THC. So we are able to produce 
extremely consistent extracts with known quantities of the primary cannabinoids 
and known quantities of at least nine other cannabinoids. We’ve characterized 
about 90 per cent of the plant entirely: so this plant is now the most highly 
characterized medicinal plant anywhere in the world. The plants are all identical 
because they are grown from clones. By doing that, then we were able to develop 
a consistent product and a series of tests which we had to agree with the regulators 
what these tests were doing; we had to validate the tests all the way through.
91 We 
produced all our own internal controls and Raphi Mechoulam, Roger Pertwee 
and Vincenzo Di Marzo have helped us to standardize internal controls so that we 
know what we’re measuring. By doing that we were able to produce a material that 
was consistent enough to meet international regulatory requirements in Europe 
and Canada, where the product is already approved, and in the US, where we’re in 
Phase IIb trials. That was the challenge, the major challenge, to make a medicine 
from cannabis. It wasn’t the cannabis aspect; it wasn’t the clinical aspect or the 
safety aspect: the challenge was whether you could actually make a modern-day 
pharmaceutical from a plant.
berridge: Could you go back in history a little bit and tell us a bit about how 
GW Pharmaceuticals was set up and where the idea came from?
Guy: [Laughs] Oh, yes, we’re in the Wellcome Institute here (Wellcome Centre 
for the History of Medicine at UCL since 2000), aren’t we? After working in 
France with plant medicines and new chemical entities, I then worked for 
Napp with opiates and did most of the early clinical development on morphine 
sulphate, the slow-release morphine, and then a number of other opiates and 
drug delivery.
92 In the early 1990s we (Ethical Pharmaceuticals) had approached 
the Home Office and said: ‘We’d be interested in looking at cannabis,’ because, 
as you know, we’d dealt with the opium plant with opiates, we knew about 
91  See note 88.
92  For details of morphine sulphate in pain, see Reynolds and Tansey (eds) (2004). See also biographical 
note on page 91.The Medicalization of Cannabis
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capsaicin and vanilloids – we’d actually been responsible for registration of the 
capsaicin product here in the UK.
93 We got a bit of a flea in our ear in the 
early 1990s, when the Home Office said: ‘No, you’re going to stick with your 
opiates.’ And, like any other pharmaceutical company or chairman, I thought 
that we had other fish to fry, and so we did. I was reminded later on that my 
interest in cannabinoids had gone back to 1982, but I had entirely forgotten 
that, as Roger Pertwee had forgotten that he wrote the first paper on THCV 
after he’d done two more with our materials.
94 
What happened is that in the middle of 1997, having forgotten that I had an 
interest in the cannabinoids, and not because I understood any of the science 
going on, only because I understood that there was a human interaction with 
the material with which those humans had co-evolved, I went to a conference 
in London held by the Royal Pharmaceutical Society and the MS Society.
95 Was 
it a half-day conference, Tony Moffat? The whole day! – I managed half of the 
day, I think. [Laughs] Clare Hodges was there talking about the medicinal uses 
93  Approvals PL 10670/0003, dated 20 August 1992, to Euroderma Limited for Axsain Cream 0-075%, 
active ingredient capsaicin HSE 0-075%, see www.london-gazette.co.uk/issues/53120/supplements/20087 
and PL 16804/0020, dated 19 February 2003, to Elan Pharma International Limited, for Axsain Cream, 
active ingredient capsaicin, see www.mhra.gov.uk/home/groups/l-reg/documents/licensing/con026456.pdf 
(both visited 15 June 2009).
94  Professor Roger Pertwee wrote: ‘The first paper to present evidence that THCV is a cannabinoid CB1 
receptor antagonist was Thomas et al. (2005). This was, in fact, my second paper on THCV – the first was 
Burstein et al. (1970). However, this first paper, published at a time well before the discovery of cannabinoid 
receptors, only alluded to the ability of THCV to behave like THC in vivo, at doses well above those we 
subsequently found THCV to behave as a cannabinoid CB1 receptor antagonist; see Thomas et al. (2005).’ 
E-mail to Ms Stefania Crowther, 8 March 2010.
95  The Royal Pharmaceutical Society of Great Britain and the School of Pharmacy, University of London, 
organized a public meeting on the medicinal use of cannabinoids at the School of Pharmacy in March 1996. 
In July 1997, the society held a symposium on the history, pharmacology and clinical uses of cannabis and 
the cannabinoids, published in a special issue of Pharmaceutical Sciences in November of that year. The 
society set up a working party in late 1997 whose objectives were: ‘To produce guidelines for pilot clinical 
trials for cannabinoids as proof of principle of their effectiveness and assist those who wish to conduct 
such trials to successfully complete them and publish the results.’ Royal Pharmaceutical Society of Great 
Britain press release: ‘Society welcomes cannabis research findings’, 11 November 1999, available at www.
rpsgb.org.uk/pdfs/pr031111.pdf (visited 15 June 2009). These clinical trials were for muscle spasticity in 
patients with MS (Dr John Zajicek, Derriford Hospital, Plymouth) and acute pain following tonsillectomy 
or abdominal surgery (Dr Anita Holdcroft, Hammersmith Hospital, London). In June 1998, the society 
gave evidence to the House of Lords select committee on science and technology. The protocols for the 
‘proof of principle’ clinical trials were launched at a meeting at the society’s headquarters in January 1999.The Medicalization of Cannabis
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of cannabis. I thought: ‘Ho hum, this is interesting. I thought it was all very, very 
taboo.’ I went to the conference and there was the MCA (Medicines Control 
Agency as they were called in those days, MHRA after 2003), the Home Office, 
some very eminent scientists – I remember Professor Patrick Wall was there as 
well
96 – there were some patients and patient groups, and a little smattering of 
pharmaceutical people I recognized, keeping their heads way, way down, because 
they didn’t want to be seen at a cannabis conference. The question arose: if 
research is to be done on cannabis, how do you standardize it? How can you 
make a material, addressing the question that you can never tell how much is in a 
pull from a joint, or how strong or weak the material is? How can you standardize 
the material and how could you then do clinical trials? Because there’s no point 
in doing clinical trials unless you have something you can make time and time 
again, fit for purpose. I stood up and spoke from the floor for about 15 minutes, 
and said that it could be done as long as you got the agreement from the Home 
Office and from the MCA, to be able to move ahead. 
Following that meeting in 1997, I was invited to say the same sorts of things 
to a Parliamentary delegation, which was led by Austin Mitchell, on the 11 
December 1997. The same array of eminent scientists and physicians were 
there: the minister was Paul Boateng. He started the meeting that was trying to 
get herbal cannabis reclassified so that research could be done. And there was 
great hope to do this because I think this was the second such parliamentary 
delegation. I hadn’t been on the first one. Paul Boateng opened the meeting and 
said, ‘Her Majesty’s Government has no will to reschedule cannabis’, at which 
point everybody’s eyes went to the ceiling. ‘However,’ he said, ‘we’d like the 
research to be done.’ At which point most people thought: ‘Well, this is bizarre 
– absolutely bizarre.’ But he did suggest that if one wanted to do the research, 
one should approach the Home Office Drugs Inspectorate (HODI). Having 
worked in one of the most highly regulated environments for the previous 20 
years with opiates and with a range of materials like that, when a Minister said 
‘Go and see my officials’, that’s what we did.
97 
A week later, I was sitting in front of the chief inspector of the HODI, Mr Alan 
MacFarlane, and said: ‘Well, you know we’ll have to grow tons of this.’ You can’t 
96  For an extract from an annotated Physiological Society interview with Patrick Wall (1925–2001) by 
Martin Rosenberg and Steve McMahon (5 February 1999), see Reynolds and Tansey (eds) (2004): 73–82.
97  See House of Lords (1998), especially Chapter 7: Changing the law on medical use and research: 
review  of  the  evidence,  available  at  www.parliament.the-stationery-office.co.uk/pa/ld199798/ldselect/
ldsctech/151/15109.htm (visited 20 January 2010).The Medicalization of Cannabis
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just get a licence for six plants. If you want to standardize material you have to 
grow 20, 30, 40 tons of the material. You have to process it and standardize it. I 
thought that would put a stop to all of it, because they had handed out licences 
in the previous years, but for probably, you know, literally half a dozen plants 
in a professor’s laboratory. They said: ‘Of course you would.’ I put a number 
of other things to them that they’d have to agree, that would have to be done, 
and they said, ‘Yes’. I said it would have to be done on a commercial basis as 
well, because no one else is going to do this. They said: ‘Well, we’d prefer to 
have GlaxoWellcome here’, but I replied: ‘I’m all you’re going to get’ because 
there was no one else who was interested in making, or thought it was remotely 
possible to make, a medicine out of cannabis, except that I’d had 20 years in 
narcotic analgesics, drug delivery, plant medicines and had retired two days 
earlier with my wife and young baby and had the time to think about it. 
They invited us to write a proposal, which was easy for us because we’d had a 
trial run with the MCA many years earlier on Chinese medicines. We presented 
that to the Home Office in January 1998, and I nearly forgot about it again, 
because I thought it would be buried in there for two or three years. About 
four weeks later I received a phone call from the chief inspector of the Home 
Office Drugs Inspectorate, who individually is probably more responsible than 
anybody else in this room for the progress of our programme, and that’s Mr Alan 
MacFarlane. He rang me up and said: ‘We’ll do this, but we don’t know how 
we’re going to do it: could you put a proposal in?’ So I put together all of the 
knowledge I had on processing opiates, cytotoxics, antibiotics, all of the rules 
to do with difficult, expensive, controlled substances from pharmaceuticals and 
put together a 22-point plan, and said: ‘I think this is how we would develop 
a medicine; how we would control it; how we would regulate it and how we 
would run it under the international Single Convention, which is the treaty 
under which they had to abide.
98 We spent some time with the Home Office 
legal officers to hammer this out, and in the beginning of June, only three or 
four months later, they were ready to issue the licence. I was in Guernsey at 
the time; we’d started a company called Guernsey Pharmaceuticals, and they 
suddenly realized that although the Home Office legislated on behalf of Her 
Majesty’s Government for Guernsey, they had no jurisdiction over Guernsey 
under the 1970 Misuse of Drugs Act. So I had ten seconds to say what the name 
98  The United Nations’ ‘Single Convention’ on narcotic drugs of 1961 is an international treaty prohibiting 
production and supply of specific drugs, which unifies and consolidates previous legislation, embracing 
nine multilateral treaties negotiated between 1912 and 1953. The UK signed the convention following the 
Dangerous Drugs Act 1964. See www.incb.org/incb/convention_1961.html (visited 15 February 2010).The Medicalization of Cannabis
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of the company would be on the licence, and my initials were GW and my 
founding partner was Dr Brian Whittle, so one way or the other, Guy–Whittle 
or Geoffrey William, I said, ‘We’ll call it GW Pharmaceuticals’. And that’s how 
GW Pharmaceuticals was created. 
If I may take two more minutes of your time, because this is for the Wellcome 
Trust, about a week later we announced these licences to the world; we were still 
doing live interviews about six or eight weeks later to world press and television. 
I received a letter from GlaxoWellcome, a rather snotty letter actually – sorry, 
you can edit that out – saying: ‘How dare you use the epithet GW? Don’t you 
understand that we’re GlaxoWellcome?’ and sent me lots of press cuttings with 
GW in, because the journalists had abbreviated their name. I did a quick search 
and rang the chap back, because I was invited to ring him before they jumped 
on us, and said: ‘It seems to me that you don’t have any trademarks, nor have 
you registered the name GW, but I will show you my birth certificate.’ There 
was a great hush at the other end of the telephone. I said: ‘Well, I tell you what, 
we’ve only been going for a couple of weeks, you can buy the name from me. 
You can buy the name for X or you can buy the whole company.’ The chap 
took me very seriously, went away for three weeks, came back and said: ‘We 
don’t want to buy the company, but we’ll buy the name.’ It took four-and-a-half 
months to come up with a four-page contract that even meant I couldn’t use the 
initials GW, but by which time we’d created press throughout the entire world, 
which would have cost millions for Glaxo to produce and when I pointed that 
out to them, they called it off. That’s why we were GW and that’s why we are 
still GW. And then GlaxoWellcome became GSK. 
berridge: [Laughter] That’s another history. It’s fascinating that the government 
seemed to have changed its position very quickly. Why do think that was? Why 
do you think approval came so quickly? 
Guy: No, I don’t think they had changed their position. If you go back to the 
year before, I think it was Lord Williams of Mostyn, the Leader of the House of 
Lords and Attorney General in 2000, who said in the House of Lords and put 
forward the government’s position: if a product could be approved by the MCA 
as an approved medicine then the government would move to reschedule that 
product – not cannabis, not the plant, not the raw material, but the finished 
product – to an appropriate schedule so that it could be used as a medicine.
99 
99  See House of Lords, Select Committee on Science and Technology (1998); (2001): sections 11–12. 
Available  at  www.publications.parliament.uk/pa/ld200001/ldselect/ldsctech/50/5002.htm#note1  (visited 
20 January 2010).The Medicalization of Cannabis
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Therefore it was the government’s position before I even got involved with them, 
because their concern was that if there is a medicine here, it must be separated 
from the advocacy debate. That was done, in a very, very straightforward way 
and very quickly then. For example, in the US, it is very difficult to separate that 
debate. The UK government was entirely consistent all the way through and we 
got an enormous amount of support from the Home Office, even directly from 
the Cabinet Office in the early days, to ensure that this programme would go 
ahead smoothly. 
berridge: I wondered whether Philip Robson, who has been involved in GW, 
would like to come in at this point? 
dr Philip Robson: Yes, I suppose I should just say that cannabis has dogged my 
career from early years of hospital medicine through clinical pharmacology and 
then psychiatry. I first became aware that it had a medicinal application as a young 
hospital doctor in London when I became aware of a patient with MS smoking 
the substance on the Victorian balcony. I spoke to the ward sister, a formidable 
woman who was very much of the old school, and asked: ‘Are you happy with 
this?’ She said: ‘Well, yes. It does seem to help him.’ I thought: ‘Gosh, if it 
convinces her, there really must be something in it.’ I spent a lot of time talking 
to this young guy and it was from him that I became aware of one of the most 
important things from the clinical point of view, as far as I’m concerned, about 
cannabis, which is that it has a very broad range of effects for people with multiple 
symptomatology. It isn’t just a pain reliever or a stiffness reliever or something 
that improves your sleep; it does an awful lot of things for people who have a 
whole range of symptoms; that became a difficult issue later when approaching 
scientifically robust clinical trials. There was a period of clinical pharmacology and 
then I became a psychiatrist and combined clinical pharmacology with psychiatry 
to establish a drug dependency unit. In this context I treated a number of people 
who had HIV/AIDS, who, again, were smoking cannabis to relieve a wide range 
of symptoms. I worked a little bit with Nabilone as a potential substitute to try to 
achieve in a pharmacologically more reliable and dependable way the effects that 
they were attaining from illegal smoked cannabis. 
At the request of the UK Department of Health, I carried out a critical review 
of the potential that cannabis might have as a medicine.
100 I think that it was 
100  Robson (1998). Submitted as evidence to House of Lords Inquiry: Cannabis: The scientific and medical 
evidence, which published its findings in November 1998 as House of Lords, Select Committee on Science 
and Technology (1998). An abridged version was published as Robson (2001).The Medicalization of Cannabis
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at the House of Lords inquiry that I met Willy Notcutt and Geoffrey Guy, 
and Geoffrey persuaded me, as is his wont, to change my career by splitting 
my time between a research fellowship at Oxford University and joining GW 
Pharmaceuticals as medical director. I think he simply needed a clinician who 
had a belief in the potential of cannabis as a medicine and someone who was 
prepared to devote time to setting up clinical trials. We created a small research 
unit in Oxford, with my colleague Derek Wade, and conducted a number of 
early trials. One of the things that we tried to do very early on – unsuccessfully, 
I have to say – was to capture this breadth of effect in a scientific way. We are, I 
think, dealing in many ways with the rather intangible experiences that patients 
have, or at least experiences that are very difficult to measure objectively. If 
you experience spasticity, there are so-called objective measures, for example 
the Ashworth scale, which many people have called objective, but in reality are 
imperfect, both in terms of their validity and reliability, and often don’t reflect 
the patient’s experience in an accurate way.
101 The struggle has been to find 
ways of measuring a symptom like spasticity in a way that has more reference 
to the patient’s experience, but at the same time is plausible and robust from 
the scientific criteria of reliability and validity. We think we have that in the 
shape of numerical rating scales or visual analogue scales. What we tried to do 
in the very early trials was to capture the breadth of experience by representing 
a number of symptoms, such as pain, spasticity, bladder-related problems and 
sleep disturbance with individual visual analogue scales, and then collapsing 
those into a composite measure to reflect this broad effect. That, sadly, was not 
a successful undertaking from a scientific point of view. I think that this is one 
of the great difficulties in working with cannabis-based medicines that have this 
breadth of effect, which patients value, while in a clinical trial context the focus 
has to be on a single symptom in a way that reflects the profile of other drugs 
– synthetic drugs – in that particular area. The unique benefit when the drug is 
used naturalistically is because of a whole range of effects, but the intensity of a 
single effect on spasticity for an individual patient may not be incredibly great. 
That has been one problem with clinical trials of a plant material. 
I think another problem has been that the ‘pariah status’ of cannabis convinced 
ethics committees and, I suppose, regulators that only if a patient had tried and 
failed every existing medicine that was available, could they go on to try the 
101  The Ashworth scale is a five-point rating of spasticity: 0: normal muscle tone; 1: slight increase in 
muscle tone, ‘catch’ when limb moved; 2: more marked increase in muscle tone, but limb easily flexed; 3: 
considerable increase in muscle tone; and 4: limb rigid in flexion or extension. Modification to a six-point 
scale was suggested in Bohannon and Smith (1987). See also Fleuren et al. (2010). The Medicalization of Cannabis
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cannabis-based medicine, which is an unfortunate thing because, of course, the 
risks involved in standard medicines are often very great and may even be life-
threatening. The risks involved with cannabis-based medicines may relate to 
intoxication and there may be long-term psychiatric risks that we will no doubt 
talk about later,
102 but, nevertheless, the actual tissue toxicity of cannabis and 
cannabis-based medicines is incredibly low and from that point of view they are 
very safe in terms of acute toxicity. Nevertheless, the necessity was, in those early 
days and still, today, to select patients for clinical trials who had already failed to 
respond to existing medicines. Inevitably there will be a number of these people 
who will not react to any medicine, which, of course, raises the threshold and 
difficulty in producing a statistically significant result. In the early trials that was 
a major problem. 
Mechoulam: Two points: one is that the discussion we are having can actually 
go back a couple of thousand years. The Romans didn’t use cannabis as a 
psychoactive agent; if they did, their literature would have said something 
about it; they didn’t. But they used it as an anti-inflammatory agent, because, 
apparently, they used cannabis that contains very low percentages of THC 
and very high percentages of cannabidiol and cannabidiolic acid. It is in the 
literature.
103 The differences between different types of cannabis that we see and 
that Geoffrey Guy has emphasized are in the literature; we should have known 
it. This is one point that I want to make. The second is that many of the major 
pharmaceutical companies in the 1960s, 1970s, 1980s and even today, had 
small groups working on cannabis. But as soon as it went up the ladder, the 
bureaucratic ladder in the companies, all of them, without exception, decided 
not to go with cannabis because of the publicity they thought they would get, 
the bad publicity: ‘This company makes money from marijuana.’ They didn’t 
want it; they were afraid of it and therefore cannabis, as was mentioned earlier, 
remained a pariah drug although it obviously has effects that are helpful and 
therapeutic. It was a pariah drug for nearly 35 or 40 years.
104
Pertwee: If I can add to that, in fact what happened, of course, is that many 
pharmaceutical companies turned to the antagonists. That was considered OK, 
102  See pages 69–70. 
103  Russo (2004b). 
104  Similarly, in the late 1960s, clinical research into the benzodioxane derivative, alprostadil (prostaglandin 
E1; Prostin VR
®; Pharmacia and Upjohn) and sildenafil (Viagra
®: Pfizer), which had been shown to increase 
mounting in male rats, was halted due to the company’s concerns about its impropriety. See Tansey et al. 
(eds) (1998): 179.The Medicalization of Cannabis
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because you were doing something that was going to block all those effects 
and so we had Sanofi-Aventis with rimonabant, etc. A lot of the other very big 
companies also had programmes for developing antagonists. Now there is much 
less interest in antagonists because of the withdrawal of rimonabant from the 
clinic for various reasons.
105 
Professor anthony Moffat: I’d like to talk about some products and the law, 
the regulations surrounding it. The regulations around the world come very 
much  from  the  World  Health  Organization  and  its  scheduling  of  drugs. 
Schedule I for drugs says: ‘This has no proven therapeutic value, and therefore 
we ban its use across the world for any kind of therapy.’
106 That manifested 
itself in this country in the 1971 Misuse of Drugs Act, and therefore cannabis 
was identified by that act, and you could not from 1971 use any medicinal 
product with cannabis in this country. The day before you could, the day 
after you couldn’t. Now dronabinol, or what we would call THC in the US, 
is the product Marinol, made by Unimed, which went into clinical trials and 
the FDA approved it, not for pain control, but for the relief of nausea from 
anti-cancer drugs and also, later on, for improvement of appetite in AIDS 
patients.
107 It went through the whole gamut and the FDA gave it a licence, 
and then the US government had to change the law within the US, which is 
unique across the world, to allow a cannabis-based medicine using THC. It 
was a synthetic THC, but derived from cannabis. Therefore they had to alter 
their laws. I just want to come onto that because it was interesting that in 1996 
the state of California decided that they would allow the use and growing of 
cannabis within what they called ‘ill patients’. So if I was ill, and I wanted to 
grow it for my own use, I could do that. Subsequently, eight other individual 
states changed their state laws to allow it as well, at which point the Supreme 
105  Professor Roger Pertwee wrote: ‘It seemed to be inducing severe depression or even suicidality in some 
patients.’ Note on draft transcript, 3 March 2010. The European Medicines Agency (EMEA) withdrew 
marketing authorization for rimonabant (Acomplia) on 16 January 2009, after Sanofi-Aventis discontinued 
its clinical development programme of the drug for treatment of obese and overweight patients following 
reported adverse reactions, including severe depression. See Wathion for the EMEA (2009), available at 
www.ema.europa.eu/humandocs/PDFs/EPAR/acomplia/3945709en.pdf (visited 20 January 2010). 
106  For Schedules I and II of the 1961 single convention, see note 98. For further details, see http://apps.
who.int/gb/ebwha/pdf_files/EB115/B115_12-en.pdf (visited 15 June 2009).
107  The US Drug Enforcement Agency (DEA) reclassified Marinol from a Schedule II to a Schedule III 
medication under the Controlled Substances Act in 1999. Not all US states have reclassified the drug. See 
www.solvaypharmaceuticals-us.com/newsroom/pressreleases/0,,14591-2-0,00.htm (visited 15 June 2009). 
See also note 9.The Medicalization of Cannabis
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Court of the land, the federal court, of course, said: ‘You bad states: you must 
not do this. You must change your laws back to where they were before because 
no state laws can supersede a federal law, which bans its use because cannabis 
and medical products derived from it have no proven value.’ Now that was 
quite interesting; that was in 2000.
108 
The following year, in Canada, a chap by the name of Terrance Parker, who 
was growing cannabis for treating his epilepsy, went to the Ontario Supreme 
Court and they said that he could do that.
109 The federal law, which banned 
the use of it like the rest of the world and the US, said it had no constitutional 
value at all. Completely the reverse situation: state versus federal law in Canada 
and the US. The Prime Minister of Canada at the time, who was a very clever 
individual, said: ‘OK, if that is so, we will not change the law. However, what the 
government will do is to grow cannabis and convert it into a medical product 
that can then be prescribed by practitioners, so they can have something to write 
down.’
110 There was an old mineshaft in the province of Manitoba and they grew 
cannabis there for years. Every year when I go across to see my colleagues in 
Canada, I ask: ‘Have they manufactured it into a medical product yet?’ And 
they say, ‘No, not yet, Tony, but we grow a lot of cannabis’. So, they haven’t 
actually moved to that situation. 
In 2005, in the Netherlands, they actually said, ‘OK, we know perfectly well 
that people are using this material’ and from 2005, again, they have not changed 
108  Fourteen states currently allow access to cannabis for medicinal purposes: Alaska, Oregon, Washington 
(since 1998), Maine (since 1999), Colorado, Hawaii, Nevada (since 2000), Vermont, Montana (since 
2004), Rhode Island (since 2006), New Mexico (since 2007), Michigan (since 2008) and New Jersey (since 
2010). Additionally, Arizona state law allows physicians to prescribe cannabis (since 1996). See Seamon 
(2006);  http://medicalmarijuana.procon.org/viewresource.asp?resourceID=000881  (visited  15  February 
2010). 
109  Mr Terrance Parker was granted a constitutional exemption to use marijuana for combating the seizures 
he suffered as a result of his epilepsy on 10 December 1997. Parker was challenged in court on 31 July 2000 
and as a direct response the Canadian government issued the Medical Marihuana Access Regulations on 30 
July 2001, which created a process that enabled certain categories of ill people to obtain an authorization 
to cultivate and possess marijuana for therapeutic purposes; see Department of Justice, Canada (2001), 
available at http://lois.justice.gc.ca/eng/SOR-2001-227/index.html; www.johnconroy.com/library/parker.
pdf; www.johnconroy.com/library/parker2.pdf (sites visited 3 February 2010).
110  Prairie Plant Systems Inc, a biotechnology company established in 1988, was awarded a five-year, $5.5 
million contract for ‘The development of comprehensive operations for the cultivation and fabrication of 
medicinal marihuana’ in a biosecure underground growth chamber in Flin Flon, Manitoba, MB, by Health 
Canada in December 2000. See www.prairieplant.com (visited 16 February 2010).The Medicalization of Cannabis
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their law, but in Groningen, in one place, they grow cannabis, manufacture it 
into a product and it is sold through pharmacies in the Netherlands. Sorry, 
when I say ‘sold’, it’s dispensed against prescriptions. But I must say that the 
patients say it is lousy and they can grow better stuff themselves.
di  Marzo:  Very  briefly,  I  want  to  go  back  to  the  stigma  of  cannabis  and 
cannabinoid research. It’s true that the major companies have always worked on 
cannabinoids: small groups getting bigger from time to time, and even getting 
to Phase I clinical trials sometimes. But there has always been a preconceived 
idea that those working on cannabinoids were doing something wrong, to the 
point that, as Raphi Mechoulam mentioned, in 1993, when the CB2 receptor 
– originally called peripheral cannabinoid receptor for THC – was discovered, 
companies saw this as a great opportunity to use THC and cannabis, or at 
least synthetic analogues of THC, to selectively target this receptor, since this 
strategy would be, in principle, devoid of any effect on the brain.
111 From this 
simple fact you can get an impression of how the stigma still operates. It’s 
almost 15 years since the discovery of the CB2 receptor and several selective 
agonists for this receptor have been developed that are totally devoid of any 
psychoactivity, so they could easily bypass all the problems of the psychotropic 
activity of cannabis, but still there has been very little clinical development, if 
any, despite the fact that such compounds might have therapeutic applications 
in the fields of pain, inflammation and cancer, where there is a growing demand 
for novel treatments.
Tansey: To follow on from the end of the previous section, we’re coming onto 
the issue of the impact of clinical trials and the setting up of clinical trials. I 
was wondering if I could ask Tony Moffat to say something about the Royal 
Pharmaceutical Society’s role in this?
Moffat: The Royal Pharmaceutical Society held a meeting about cannabis as a 
medicine in 1996 and it was a lively meeting. I can remember Clare Hodges 
being there. Afterwards, Anita Holdcroft and I were there together with the 
dean of the School of Pharmacy, and she said: ‘Why doesn’t somebody do some 
clinical trials?’ She wanted to treat people like Clare and others, who had MS, 
but she felt that she was inhibited because no clinical trials had been done. I 
thought: ‘Well, she’s absolutely right. The clinical trials that had been carried 
out were either too small – 20–30 patients – or had no real objective endpoints.’ 
So, together with Vivienne (Viv) Nathanson, the chief of policy at the British 
111  See Munro et al. (1993). The Medicalization of Cannabis
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Medical Association (who was invited here today, but was unable to attend), I 
went to see the Chief Medical Officer and said: ‘What do you think? Is it time 
to do this? What would the government view be?’ He said: ‘Go for it: let’s do it.’ 
I phoned up Alan MacFarlane, the chief inspector of the Home Office Drugs 
Inspectorate, to whom Geoffrey Guy has already alluded – I used to work for 
the Home Office so I knew all about that – and he said: ‘Nothing against it, 
Tony, but you need a good proposition.’ So, we thought: ‘OK, how do we move 
forward?’ And Viv suggested that I ask Sir William (Bill) Asscher, then head of 
the medical school at St George’s Hospital, London, to chair a meeting and get 
all those people who might be concerned in running clinical trials and actually 
do it. So we thought: ‘Right. That’s exactly what we’ll do.’ So, the remit, which 
Bill put down quite clearly, was: ‘We’re going to have three meetings. At the end 
of that we want at least clinical trial protocols which will be proof of principle.’ 
The kind of people we got were Roger Pertwee from Aberdeen and one of his 
colleagues, Dr Derrick Bennett, who also came as a statistician, the number 
cruncher who told us how many patients we wanted. We didn’t really want to 
listen to him, because every time we talked to him the numbers went up. We 
had Anita Holdcroft, who was going to conduct the trial afterwards. We had 
Peter Cardy and his representatives from the MS Society.
112 We had an MRC 
representative and somebody from the Wellcome Trust to the first one, after 
which the MRC said: ‘Look, if this is going to be funded, we’ll take it on. That 
doesn’t mean to say we will, but we will help you put the bid together and make 
sure that it doesn’t fall into a pit.’ The Wellcome Trust therefore backed out. We 
had a huge meeting where we launched – I should say the Royal Pharmaceutical 
Society launched – two protocols for two clinical trials.
113 One was John Zajicek 
from Plymouth, who can’t be here today, a multiple sclerosis trial, and the other 
was Anita Holdcroft as the principal investigator on pain. 
Part of the problem was, of course, getting Home Office approval. They said: 
‘No problem at all. We can do that.’ I was already working with the MCA, 
who said: ‘We can get you an exemption for a clinical trial certificate.’ No 
barriers there at all, but we had to have something to give to people. The MS 
Society was quite keen that their patients would take part in this and they 
said: ‘Recruitment of patients would not be a problem through the hospitals, 
112  Peter Cardy was chief executive of the Motor Neurone Disease Association, chief executive officer of 
the MS Society of Great Britain and Northern Ireland, and chief executive of Macmillan Cancer Relief 
(2001–07). See Brown (2002).
113  See note 95.The Medicalization of Cannabis
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we could promise you it was OK.’ Anita and her colleagues in pain control 
and anaesthesiology in hospitals didn’t think recruitment would be a problem 
either. But it came down to the question of what we were going to give to 
the patients. I contacted the CEO of Unimed, who made Marinol, and they 
were very keen: ‘We’ll supply you with all the Marinol you like. We make it in 
2.5 mg, 5 mg and 10 mg capsules. What do you want?’ They gave us the 
equivalent upfront of something like £500 000-worth of capsules for the trial. 
I should explain that the clinical trials were going to be in three different 
arms: in the first, patients would receive cannabis; the second one was a 
placebo; and the third was THC on its own – the Marinol from Unimed. The 
concept was that comparing the cannabis and the placebo together would 
answer the question: ‘Is there any clinical effectiveness of the cannabis above a 
placebo?’ And by comparing the cannabis to THC we hoped it would answer 
the further question: ‘Is it just due to the THC?’ So we got the THC part. 
There were two people I wanted to ask if we could use their materials: one was 
Geoffrey Guy, who kindly said yes, we could have the supply of his material, 
but since he was just organizing his new company, although he could provide 
the material that we could use, we would have to pay for it. The other was the 
European Oncology Institute in Berlin (the Institut für klinische Forschung) 
and they said we could have their product and it would be free. So I said: 
‘Sorry, Geoffrey.’ Looking back on it, that might have been a mistake, but that 
was the way it was then. In terms of what we grew, we asked the people in this 
country what varieties of cannabis they used. For various political and legal 
reasons we produced one huge batch that was grown in Switzerland under state 
authority. It was then imported into Germany where it was manufactured into 
capsules and then imported into this country, and the Home Office was very, 
very helpful in doing that. I think it was true internationalism. It was only 
‘proof of principles’, but nevertheless I think honours are due to the people 
who provided us with the materials, the government agencies who did it, but 
most importantly to those two principal investigators, John Zajicek and Anita 
Holdcroft, for going forward with it for the benefit of the patients. What we 
were trying to do, the whole essence of what the Royal Pharmaceutical Society 
of GB was trying to do, was to make life better for MS sufferers and pain 
control afterwards, because there weren’t too many good drugs around. That 
was our driving force. 
Tansey: Anita, could I ask you to take up the story, please, on your involvement 
in the pain clinical trials? The Medicalization of Cannabis
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dr anita  holdcroft:  I’ll just reverse back a little into 1994 because I was 
running a pain clinic then at the Hammersmith Hospital, London, at the Royal 
Postgraduate Medical School. A patient came in one day and filled in my pro 
forma and he said that he used cannabis to help his pain. It was in the context 
of the scientific findings: we knew that there were cannabinoid receptors in 
the body. I turned round to him in his first visit to the clinic and said: ‘Right, 
well, you’ve got to do a randomized placebo controlled trial.’ And he said: ‘Oh 
yes, if that’s what you want me to do, I will.’ I didn’t know where I would get 
any supply from, but he had a condition that really made me think it would 
be amenable to cannabis, because he not only had pain, but inflammation as 
well, and I was aware from the scientific literature that cannabis might well 
help inflammation. He had an inflammatory condition of his gut called familial 
Mediterranean fever. Well, I guess none of you have heard of it.
114 But it was 
when the Home Office came along and said: ‘Anita, you must do more of these,’ 
and I couldn’t, because there really wasn’t any other patient with that diagnosis 
in my pain clinic. He was a smoker of cannabis; he took oral morphine to 
manage his pain and had difficulties with the side-effects from oral morphine 
and said that taking the cannabis helped him keep the dose of morphine down. 
He also described his experience in hospital: he’d been hospitalized on a number 
of occasions and, of course, if you smoke cannabis you’ve got to go outside 
the hospital, because it sets the fire alarms off otherwise. Anyway, that came   
out subsequently. 
Also, in the scientific literature there was a paper by Fred Evans, who was a 
professor of pharmacognosy at the School of Pharmacy.
115 He’d written about 
pain and inflammation in 1991 and I realized that in previous studies the 
subjects had not been naive to cannabis, so he was a particularly useful patient 
to have in front of me in the clinic. I went along to see Fred at the School of 
Pharmacy and he carried a licence to grow cannabis, so over some coffee and 
a little bit more discussion, we decided that we would consider whether or 
not we could supply this patient with appropriate medication. Professor Evans 
took this proposal back to his colleagues and it was the School of Pharmacy, 
particularly Professor Michael Newton, who made the capsules for me by hand 
114  Familial Mediterranean fever is an autosomal recessive disease characterized by recurrent episodes of 
fever  accompanied  by  peritonitis,  pleuritis,  arthritis  or  erysipelas-like  erythema.  See  Ben-Chetrit  and 
Touitou (2009).
115  Evans (1991).The Medicalization of Cannabis
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for this particular study.
116 They were fragile; the patient had to keep them in the 
fridge. I was also up against barriers such as the capsules being an unlicenced 
preparation; the cannabis had to be standardized. When it was standardized, 
and the combination of CBD and THC was publicized (at an open public 
meeting at the School of Pharmacy held during Science Week in 1996), people 
looked at me and said: ‘Oh, that’s an ancient preparation of cannabis you’ve 
got there,’ because it had quite a high content of CBD in it. It was important 
to get the hospital pharmacy on board with me, because it was an unlicenced 
preparation and I realized that if I was going to prescribe it, which I would have 
to do, I would need the various regulatory tick boxes to be agreed. It had to 
go through the ethics committee and one of my colleagues in anaesthesia was 
a member. He said that they’d really had a good discussion over this because it 
was so enterprising and they considered that it was the right sort of study for the 
Royal Postgraduate Medical School to be doing: it was a first, it was innovative 
and, yes, I should proceed. That was one problem solved. 
Because we had the School of Pharmacy working with us, we’d found out what 
cannabinoids were in the capsules and the MHRA agreed that we could have 
their exemption. Then the Home Office came into the story; actually they 
invited themselves. Home Office regulations required that the cannabis was kept 
under lock and key, so we had to see the real locks and keys in the pharmacy. 
They also sat me down, one of them was Alan MacFarlane, but it must have 
been in his younger days because this was the early 1990s, and said that they 
wanted us to study more patients; he also put me under surveillance, and later 
my husband said: ‘Please don’t do this study, because our phones are being 
tapped.’ It was very interesting, because MacFarlane came again in the year 
2000 when we were setting up the MRC study and said: ‘Oh Anita, we’ve lost 
all the paperwork on you. We’ve got to start again, but it won’t be surveillance 
this time, don’t worry.’ [Laughs] I think they themselves were under different 
regulations in those times. 
In that first Home Office meeting, one thing that MacFarlane stressed was: 
‘You must never trust patients who take cannabis.’ Well, I took that with a 
pinch of salt, because, you know, if patients are taking cannabis as a medicine, 
they have some ideas they can share with us, about how to use it as a medicine, 
in contrast with recreational use. He put me in touch with Brian Smith at the 
Maudsley Hospital, London, who was a biochemist, and we agreed that we 
would make sure that the patient was compliant and would take his medication 
116  See, for example, Jover et al. (1996). The Medicalization of Cannabis
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as he should, using urinary analysis for monitoring. Brian was our expert in 
cannabis biochemistry. First, we took a urine sample, which we never published 
while the patient was taking his own cannabis as a medicine; enough said about 
that. We wanted the cannabis washed out, so we did this before we started a 
dose-finding study. The patient then took different doses over about 10–12 
days and from that we determined the dose that we were going to give him as 
pain medication. It was 10 mg, based on the THC content. The difficulty with 
these preparations is that you have the plant extracts but you’ve got to have a 
dose to write on your prescription form, so the dose was based on the THC 
content in the capsules. The study ran for six weeks, three weeks with placebo, 
three weeks with the active preparation and the patient was compliant. You 
can read the details in our paper.
117 His cannabinoid levels came down during 
placebo weeks but they didn’t come down to zero because cannabinoids are fat-
soluble and stay on board in the body, but they were not at levels that have any 
clinical activity. The patient found that after a couple of days, he knew whether 
he was on the active capsules or not, which, again, is a confounding factor in 
a clinical trial, yet something that was helpful to know. In his placebo weeks, 
because he knew down the street was the place where he could get something 
that would relieve his pain, it was quite difficult to counsel him over the phone. 
Again, I think this is something that matters in clinical trials when a patient can 
access the preferred drug outside the medical consultation. You need somebody 
there for your patients to talk to so they will maintain their compliance. We had 
to talk him through that difficulty. And then in the last two weeks, one active 
and one placebo week, he wasn’t sure himself what he was taking, whether it 
was the active preparation or not. This is why we wrote: ‘Is there a withdrawal 
phenomenon; is there tolerance to the drug?’
118 Those were questions that were 
raised from this study. I then experienced an author’s dilemma, because one 
general publisher in this country, an editor, phoned me up and said: ‘We will 
publish this case report if you say he was a habitual user.’ Now this raised ethical 
problems, because it was not legal to use cannabis and the study was an n of 
1 so it would be relatively easy to identify the patient. Needless to say, it was 
published in another journal without a caveat.
119 
At the same time, I was making an application for a study to investigate the 
efficacy  of  cannabinoids  on  MS  with  a  randomized  controlled  trial  at  the 
117  Holdcroft et al. (1997a).
118  Holdcroft et al. (1997b).
119  See note 117.The Medicalization of Cannabis
50
Central Middlesex Hospital. The application went to the MS Society but was 
turned down. I think that was before all the lobbying started by the BMA and 
the House of Lords, then culminating in the Royal Pharmaceutical Society 
workshops that Bill Asscher set up, that we’ve heard about from Tony Moffat.
120 
These workshops on the use of cannabinoids in pain management and multiple 
sclerosis set us off on the right track and then the MRC set up their own 
workshops, so we had experts come in to say how we should run the trials. 
In postoperative pain, you need to recognize that in addition to wound pain, 
patients often feel nauseated, there is also an inflammatory element and often 
muscle spasm around the area where the surgery has taken place. Having a pain 
medicine that acts on all these would be quite useful to patients. How the pain 
study was set up was interesting. Again, we didn’t know the dose so we designed 
an open label dose-finding study, and that was the study that was published.
121 
But in that dose-finding study we were limited to a single dose. We had to have 
patients with moderate pain agree to be studied for six hours with only cannabis 
as their pain medication. That was not easy postoperatively. Yet again, we found 
doses of cannabis that were effective; the efficacy of the cannabis was similar 
to that of paracetamol, which is a moderate analgesic. This study has shown 
that as the dose of cannabis increases, postoperative pain relief also increases. 
We published the results in 2006, so almost ten years after we first set up the 
workshops to develop the clinical trials.
122
Tansey: So your first trial, Anita, was an n of 1. When did you publish that?
holdcroft: That was published in 1997. It was completed in 1995, after having 
gone through all the regulatory procedures over the previous year.
Tansey: And then when you were doing the MRC trial, how about patient 
recruitment? How did you recruit patients to that?
holdcroft: It was interesting, because the people who’d helped set it up, had set 
it up to use a score for pain relief after surgery. Patients could only enter into the 
study if they’d had morphine after surgery. Also, the patient selection was very 
rigid. In the end, it was only possible to get a handful of patients recruited so 
we had to expand the protocol – increase the ages of the patients and the types 
of patients who could go on the study – to be able to recruit enough patients. 
120  See pages 44–5. 
121  Holdcroft et al. (2006). 
122  See note 121.The Medicalization of Cannabis
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In the end, it probably took us two years longer than we anticipated to do 
the dose-finding study and then the MRC stopped us continuing on the main 
randomized placebo-controlled study. 
Tansey: What happened when the MRC pulled the plug?
holdcroft: We redesigned the study using the remaining grant money, but they 
said that we could no longer proceed.
Tansey: When this trial was going on, was it simultaneous with the MS trial?
holdcroft: Yes, with John Zajicek’s study on MS.
123
Tansey:  Unfortunately,  John  Zajicek  can’t  be  here.  The  observation  that 
cannabinoids might be useful for MS, was made first, I think, by Professor 
Baker.
Professor  david  baker:  I guess my interest in cannabis really stems from 
around 1998. The MS Society, who’d supported me for much of my career, had 
obviously started to listen to people who said: ‘Well, maybe cannabis works.’ I 
was invited to a symposium on MS at the University of Edinburgh (sponsored 
by the Scottish MS Society) in January 1998. I met Roger Pertwee there, and 
Lorna Layward, from the MS Society, who said: ‘Well, you know, you do 
experimental work on MS, why can’t you just do something and see if it works 
or not.’ So, I thought: ‘Well, I’m game for those types of things.’ My background 
was immunology and at the time it was thought that MS was just a problem 
of the immune system, and I said to Roger: ‘What drugs can we get and what 
can we try?’ It was difficult initially for us to get cannabis, because we’d have to 
get a Home Office licence, so he said: ‘Well, try a synthetic compound. It’s very 
potent at the receptors and very cheap. It will stimulate both CB1 and CB2 
receptors and we will see what happens.’ We did the experiment and we have a 
model where animals get paralysed and get better and get paralysed as happens 
in MS; and we gave the drug and nothing happened. It just didn’t work. We 
published that ten years later in 2008.
124 
However, at the time of doing that work, because we were actually interested 
in treatments for MS; we’d got our new wonder cure, as every scientist has, you 
know, the thing they are working on at the moment. We’d been doing some 
very long-term experiments on animals and we actually noticed a mouse that 
123  Zajicek et al. (2003).
124  Baker and Pryce (2008). The Medicalization of Cannabis
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had a really bad tremor. I thought: ‘People with MS aren’t really using it to stop 
their relapsing attacks, they’re using it for symptoms.’ So, we thought maybe 
we could have a go. Once we got permission to do that, we gave the drug, and 
lo and behold, the tremor went away. We thought: ‘Great!’ We’d filmed this 
and we rushed over, I think, to give it to Lorna Layward, who was going to the 
House of Lords, probably with Tony Moffat, to talk about doing the trials.
125 
So she had the data and she could see it with her own eyes. She asked: ‘Well, 
what about spasticity?’ I said, ‘Well, I don’t know if it happens.’ We went back 
and we looked at the animals and, sure enough, we could see some animals that 
had very stiff limbs. That was because we’d been doing these very long-term 
experiments that normally people don’t do. We gave the drugs and we could 
see that the muscles started to relax and we thought: ‘Brilliant!’ We could see it 
happening before our eyes, but that was not going to convince anybody, so we 
had to measure it. We contacted our friends in the clinic and asked: ‘How do we 
measure it?’ It took us about six to seven months to devise some equipment that 
allowed us to measure it, and, sure enough, we could give cannabinoid receptor 
agonists that would alleviate the symptoms. 
The important thing, which really clinched it for us, was when we started to 
block the cannabinoid receptor system and things got much, much worse. 
That told us that there was something important here. It’s not the fact that you 
stimulate a receptor and it gets better; well, that could be just because they’re 
high as kites or whatever. It was really when we blocked the system and found 
that things got worse that told us that there was something that was regulating 
it  internally. Then  Vincenzo  Di  Marzo  was  very  kind  and  looked  at  the 
endogenous system and we started to get the information that this endogenous 
system  was  trying  to  regulate  these  symptoms. That  started  us  thinking: 
‘Maybe this is why it is controlling the symptoms; maybe what’s happening 
is that these natural cannabinoids, endocannabinoids, are acting as brakes to 
limit excessive nerve signalling which may occur in MS.’ Essentially, two years 
later, it transpired that the cannabinoid system was shown to be a regulator of 
the way nerves transmit information across synapses. Diseases, neurological 
diseases, are all a problem of altered neuron transmission. Once you start to see 
that the cannabinoid system can regulate synaptic neuron transmission, it then 
starts to fit into place, why cannabinoids can be beneficial in treating a number 
of symptoms: pain, spasticity, etc. You can also understand why cannabis can 
have adverse effects, such as psychosis: it is because the body is using that 
125  See page 45. The Medicalization of Cannabis
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system to regulate nerve transmission whose outcome depends on which area 
of the brain it stimulates. That’s where we got the excitement. I think at the 
time we were doing this, it was very fortuitous that we were doing the basic 
science at the same time that Tony Moffat and John Zajicek were doing the 
trials with the MRC and Geoffrey Guy was initiating his company. It started 
to put biology behind the patient perspective, so I think what it did was to give 
an indication that there is biology that these drugs are working on. We don’t 
really understand the biology, but nevertheless there is biology, and the more 
we understand about it, the more we’ll understand what these different drugs 
and the components in cannabis do. I guess at the time, it told us that maybe 
cannabis does have some usefulness medicinally.
Tansey: Could I ask the clinicians what impact, if any, that work had? Did 
people immediately pick it up? Did it seem to have some clinical relevance? 
dr William notcutt: Yes, we picked that up. I was coming to this as a clinician 
having dabbled in some research into Nabilone in the mid-1990s and done 
much more research since, particularly in this area. These sorts of things were 
gradually becoming general knowledge. From my own point of view, as a pain 
clinician in the early 1990s, the scenario then was that we had opioids, non-
steroidal  anti-inflammatory  drugs  (NSAIDs),  tricyclic  antidepressants,  anti-
convulsants, all with their own problems. All were potentially lethal in overdose 
and had side-effects. We were still seeing a lot of patients for whom we had 
no pharmacological answers to their chronic pain. This led me to start using 
Nabilone, a synthetic cannabinoid, as an agent and gathering up a group of 
patients and observing them. I found out that one-third of them said: ‘Yes, it 
works’; one-third said: ‘Well, it probably works, but I don’t like the side-effects’; 
and the rest said: ‘Thank you very much, but it doesn’t work.’ All of them said 
– and this was one consistent thing that came across from all of those who had 
previously used cannabis as an alternative – that cannabis was better. Was it 
because of the delivery method, was it something intrinsic in the material used, 
or what? At that time, we didn’t know. 
From that point of view, I linked up then with Clare Hodges, with Geoffrey Guy 
and others, and the process started moving forward. Clearly what we wanted 
to do, rather than to use Nabilone, a synthetic compound and a chemical, was 
to start to explore the uses of cannabis. Again, I was hearing the stories from 
patients, a few of whom actually put cannabis on my desk in my consulting 
room saying: ‘What do I do with this, doc?’ [Laughs] I’ve had that several times. 
The excitement for me was when we eventually had a preparation that one could The Medicalization of Cannabis
54
figure 2: Two of the earliest group of patients being dosed with Sativex under supervision 
at the James Paget University hospital, Great Yarmouth, mid-2000.
left to right: patient, Geoffrey Guy, patient, William notcutt, sue simmons, nurse.
figure 3: study team at the James Paget University hospital, Great Yarmouth in 2000.
left to right: cathy sansom, nurse; Mario Price, pharmacist; sue simmons, nurse;  
William notcutt, anaesthetist; sam Podmore, research assistant.The Medicalization of Cannabis
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give to patients that was purified and looked like a medicine, was consistent 
and did what it said on the tin, to copy the advert.
126 Then we could start to 
do serious clinical trials but initially we had no knowledge of what was going 
to happen. So on 1 May 2000 the first clinical trials started on GW products 
(Figures 2 and 3). We were sitting in an old, disused ward at the James Paget 
Hospital, Great Yarmouth, and we started out with n of 1 studies.
127
Soon afterwards, Phil Robson and Derek Wade in Oxford also started these sorts 
of studies to see what happened when we gave real patients this new material. 
As we’ve said before, all were end-of-the-line in terms of treatment; probably 
the worst patients to study, because they are generally very complex, sometimes 
very frail and difficult to study. That provided us with a body of information 
that could then lead on to the more definitive studies, the tighter studies, the 
randomized controlled trials that have emerged from the GW stable over the 
last seven or eight years. 
Over that time, we also gathered a large clinical experience using cannabinoids 
and one of the things that’s been striking to me as a clinician using a range 
of other drugs is how safe these drugs are and how the side-effects are less 
unpleasant  than  those  from  morphine  and  tricyclic  antidepressants.  Even 
now, we’ve been starting to use a drug called ketamine as an analgesic, which 
has hallucinogenic effects.
128 So, in terms of all the other drugs we use in pain 
medicine and how we’ve got used to using them, my colleagues and I have 
become very comfortable with the use of cannabinoids.
Guy: I think the question was ‘by how much’ did the primary science influence the 
clinical use. Our programme was born out of straightforward medical empiricism. 
A large number of patients have reported, in the vernacular, that use of street 
cannabis in smoked, cooked or other forms, was giving them marked benefit. My 
temptation was to believe them. Why other people didn’t, I’m not sure. What was 
interesting when we started the programme was that as soon as we announced it, 
people started writing to us. We had a secret address and still do, but they wrote 
to the newspapers that covered the stories; they wrote to the BBC; they wrote to 
the Home Office. We used to receive a mailbag from the Home Office once a 
126  The phrase: ‘Does exactly what it says on the tin’ was coined in a UK television advertisement for 
Ronseal Quick Drying Wood Stain, which first aired in 1994. 
127  Notcutt et al. (2004).
128  Ketamine is a short-acting but potent anaesthetic with hallucinogenic effects. See Hardman and Limbird 
(2001): 346–7.The Medicalization of Cannabis
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week. Over time, we had about 4500 patients who wrote to us and about 30 per 
cent of them had experience with cannabis. We then drew up, I think, a 70-point 
questionnaire and wrote back to them all. We wanted to know everything about 
what they did: where they found their cannabis; what type it was; whether they felt 
some was better than others; what caused them to take more; what caused them 
to take less – supply was the problem that caused patients to take less, not side-
effects – and what other medicines they’d been on. We began to form a very, very 
clear picture and we published that data about five years ago.
129 We found a very 
clear picture of what the material could do and what we had to do then was to try 
to maintain that. Information from David Baker’s research, and a lot of research 
throughout the world, was beginning to add biological and scientific credibility 
to a quality of data, which sadly in this day and age, physicians don’t heed very 
well. I think it is at their risk that they don’t heed and don’t seem to listen to the 
patients. I know that David’s study was absolutely heralded as ‘the actual proof’, in 
that six mice got better; so that was fine. The fact that we had 4500 patients, 1000 
of whom had got better, was irrelevant, because it was a different quality of data. I 
think what you have to do is to work out the difference between what impacts on 
developers like us who have to start from scratch to see where we’re going to take 
a programme, as opposed to what impacts on those people who edit journals and 
who want the objective, scientific ‘truth’, given in a very nicely wrapped-up way.
Tansey: What happened to all the letters? Do you still have them?
Guy: My wife and I used to read them on a Saturday morning because they were 
addressed to me initially. If ever you’d had a bad week, you’d read some of these 
letters. But you would distinguish between those people with pain from MS, 
who wrote about a very different type of paradigm from those with arthritis. It 
was as if 20 of them had sat around a table and said: ‘What should we write to 
Dr Guy?’ The corroboration in what they said was stunning. It was a stunning 
piece of evidence, and we still have them all on file, and the survey as well. 
Tansey: They are a fascinating resource for medical historians.
Guy: I think they would be, but they would have to go back and get permission, 
but I think nearly all our patients would be happy. Also, the letters we used to 
get often used to come with: ‘And this is what I smoke, doctor.’ Fortunately, the 
licences were given to me personally so it was legal for me to have them, but we’d 
have piles of all sorts of stuff, cookies made for us and all sorts of things. [Laughs] 
129  Between 1998 and 2002, 3663 questionnaires were distributed, with 2969 returned, an 81 per cent 
response rate. Ware et al. (2005). The Medicalization of Cannabis
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hodges: I have lots of letters that were sent to me with the same sort of thing, 
and I don’t know what to do with them. 
Tansey: We’re happy to talk to you afterwards about depositing them.
130 
Robson: I wanted to add that in these very early days, we did spend an unusually 
large amount of time actually talking to patients. That becomes less and less 
possible when you get into big clinical trials. In these early studies, a very striking 
thing was the variability of response. One of the great difficulties in using these 
medicines is the procrustean temptation to fit the prescribing routine to the 
convenience of the physician, or as a regulator would prefer it, when, in fact, 
because of the immense variability in both response of symptom relief and 
unwanted effects, the need for each patient to be able to determine their own 
dosing paradigm is important for this group of medicines. Obviously, when you’re 
smoking cannabis to relieve symptoms you have the ability to titrate exactly as 
you wish it. But we have found it is very important when using cannabis-based 
medicines, to retain that self-titration element, as the individual patient is the 
one who best knows how he or she is reacting. I think that’s a very important 
thing that we’ve learned and incorporated now into the big randomized studies 
that have at last been showing a positive effect very convincingly. 
Tansey: As part of that issue of self-titration, does drug delivery play a part 
in this? 
Robson: It does. I think that our particular system, which involves a mouth 
spray as opposed to a capsule or a tablet, does lend itself to that tremendous 
flexibility, because the patient can very conveniently carry this around in a 
handbag or a pocket (Figures 4 and 5). It’s very easy to dose at any time, you 
know, someone could dose right now at this meeting without water or anything 
of that sort, and therefore the medicine can be taken through the day exactly 
as the individual needs it. Also, the advantage of an oral mucosa spray is that at 
least part of the preparation is absorbed through the buccal mucous membrane, 
not the gut.
131
notcutt: I was going to briefly add that I think that during the 1990s we 
also got used to the concept of patient-controlled analgesia with opiates after 
130  Staff from the archives and manuscripts department of the Wellcome Library, London, have been in 
touch with Dr Clare Hodges and it is hoped that it will be possible to arrange for deposit of the letters there 
(March 2010).
131  Dr Philip Robson wrote: ‘The buccal membrane offers a potentially useful route for systemic drug 
delivery. See Shojaei (1998).’ Note on draft transcript, 10 March 2010.The Medicalization of Cannabis
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surgery. Prior to that, we had also had Cicely Saunders, the founder of the 
modern hospice movement, recognizing that self-dosing of opiates by patients 
with cancer, for example, was critically important, and that while the physician 
didn’t know what the dose should be, the patient did.
132 The patient knew when 
they were dosed to both optimal effect and minimal side-effect. They will go to 
the point where they say: ‘That’s enough, thank you very much.’ We have seen 
exactly the same in the use of Sativex as well – both effect and side-effect. So, I 
think this has been built on our experience with opioids, both in chronic pain 
and postoperative pain.
Tansey: It also emphasizes listening to the patient?
notcutt: Listening to the patients, yes. 
holdcroft: I think it’s important to recognize that patients in hospital don’t have 
access to smoking facilities, yet that is fairly common for cannabis medication. 
We found smoking to be frequent in our studies of HIV patients and patients 
with sickle-cell disease.
133 I have corroborative letters too, but I think the hospital 
experience with people who are taking cannabis as a medicine unlawfully is that 
132  Saunders (1964); Clark (1998). See also Reynolds and Tansey (eds) (2004).
133  Howard et al. (2005); Woolridge et al. (2005).
figure 4: The first canisters of the cannabis spray that was to become Sativex, 2000. 
figure 5: Sativex oromucosal spray, 2009. The Medicalization of Cannabis
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it is very difficult to get a handle on what pain they may suffer. For even though 
I know how and what they are going to use at home, I think hospital-based 
patients have to have a cannabis preparation that is going to work in hospital 
because it may not be possible to self-medicate. Even today, patients may still be 
denied access to cannabinoids on prescription by healthcare staff.
Mechoulam: We did several clinical trials; I’ll tell you about two of them. One 
had to do with children with cancer. Unfortunately, young children – babies 
even – get cancer, it’s an extremely difficult time for them and for their families. 
We decided to go ahead; we had these young children from the age of several 
months to the age of 13; we gave them THC under the tongue.
134 It’s difficult, 
obviously, to have them smoke and it is unpleasant for them to have another 
injection. We gave them THC under the tongue and initially the experiment 
was supposed to be blinded, i.e. giving the placebo to one group and THC to 
the other. Then the physician who did the work, Professor Aya Abrahamov, 
decided that, ethically, she could not do it, because all the children who got the 
THC stopped vomiting and didn’t have nausea, and she could not go ahead 
giving children placebo when she knew that she had a compound that helps. 
So, ultimately she gave it 400 times: we didn’t get a single case of nausea or a 
single case of vomiting: it completely blocked their nausea and vomiting; it had 
nothing to do with the cancer itself. We had problems publishing the results 
because we didn’t have parallel placebo work.
135 
The other trial was done with collaborators in Brazil. At that time it was almost 
impossible to do clinical trials elsewhere and in Brazil they had good relations with 
their Ministry of Health. This was, I think, the first clinical trial with cannabidiol 
used in patients, a small number of patients that had intractable epilepsy of a 
certain type – I won’t go into details here – and they found that high doses of 
cannabidiol, 300 mg per day or 200 mg per day for months, lowered the number 
of epileptic attacks that these patients had. We had to supply the Brazilian group 
with huge amounts of cannabidiol, almost half a kilo after a certain amount of 
time. We had special chromatography columns built for this purpose. Fortunately, 
the Brazilian colleagues didn’t use all of it and they went on for another 15 years 
using cannabidiol with various types of patients and found that it reduced anxiety 
and has effects in certain neurological diseases.
136
134  Professor Raphael Mechoulam wrote: ‘In a solution of olive oil.’ Note on draft transcript, 9 March 2010.
135  Abrahamov et al. (1995).
136  Guimarães et al. (1994). The Medicalization of Cannabis
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Tansey:  We  held  a  Witness  Seminar  in  2006  on  platinum  compounds  in 
chemotherapy, with paediatricians and oncologists there talking about using 
cannabis, exactly as you’ve described, particularly for children, although that, of 
course, has been superseded by a lot of more modern drugs, but we had these 
accounts in that seminar as well.
137 Would anyone like to make any further 
comments about clinical trials or clinical work before I hand over to Virginia 
Berridge, who will lead the discussion of patient experience and activism?
dr ethan Russo: We’ve heard about therapeutic applications in clinical trials, 
but I would like to mention a situation that comes from a different point of 
view. It was in patients using cannabis already. This is a story from across the 
pond in the US. Despite their political stance, there has been a programme in 
place since 1976 called the Compassionate Investigational New Drug program 
(Compassionate IND) by which, before 1992, patients who proved their clinical 
need for cannabis could get it supplied by the US government (National Institute 
on Drug Abuse), using cannabis that’s grown at the University of Mississippi. At 
the turn of the millennium, I was having trouble getting clinical trials started 
in the US and I decided that I had better look at a group of patients who had 
cannabis legally, under this programme.
138 There were seven surviving patients 
at that time (2001). We looked at four of them. Three could be brought to the 
clinic and one was studied at home in the state of Iowa. These were patients 
who were smoking up to 10 g of cannabis a day for a variety of conditions: two 
had rare inflammatory conditions with pain – multiple cartilaginous exostoses 
(hereditary exostosis); one with nail-patella syndrome; one had glaucoma; and 
one had MS with a variety of problems, including spasticity and difficulty 
speaking. They were subjected to a battery of tests; we tested everything that 
had been reported as a sequela of cannabis use, including magnetic resonance 
imaging (MRIs), electroencephalograms (EEGs) and neuropsychological tests. 
To make a long story short, the only significant findings you might imagine were 
pulmonary sequelae; there were some minor changes in pulmonary function in 
these patients. Unlike in most tests, because they were smoking at the time of 
the testing, they did have minor changes in higher executive functions, but they 
all functioned well. I should mention that one of these people was a full-time 
stockbroker and very successful. He had been using cannabis at this very high 
rate for some 20 years. But immunologically, electroencephalographically, MRI 
imaging, all of these tests were otherwise quite benign, thus demonstrating that 
137  Christie and Tansey (eds) (2007): 47.
138  Russo et al. (2002).The Medicalization of Cannabis
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even with high levels of daily usage this seemed to be a very safe drug. The only 
problems seemed to be attached to smoking, as you might imagine. This was an 
important finding. At the time no one had studied these patients, but through 
an inability to do clinical trials of my own design, I had to resort to this. I 
think we’re finding subsequently, as very much larger clinical trials with non-
smoked cannabis have become available, that very much the same thing has 
been evident, that the adverse event profile is very, very low and, as mentioned 
previously, standardized cannabis materials compare extremely favourably to 
existing drugs so there is reason for optimism from this point forward that these 
agents will be available to treat a myriad of difficult clinical conditions in a   
few years.
139
berridge: Our last theme is the role of patients in pressing for changes and we’ve 
already heard something about that so far, but we’d like to devote the last part 
of this seminar to that, and wondered if Clare Hodges would like to open this 
session by talking about her experiences? 
hodges: My personal experience, which is how I first came across cannabis 
was that I started smoking it in 1992, after I’d had MS for ten years. I found 
this helpful in all sorts of ways: relieving pain, stopping spasticity, helping 
me to sleep, helping me to eat. I wanted to find out if it did the same for 
other people as well. I brought this about via doctors, newspapers and TV, to 
find out if there was anyone else with this experience, and there was. Then I 
wanted some scientific evaluation of what happened, because before then it 
was just anecdotal evidence: people said it helped them with this or that, but 
I wanted some kind of scientific evaluation and some trials, to find out if this 
was recognized by anyone. I wanted to get some trials done somewhere, which 
is where the idea for most of these trials that everyone has talked about came 
from. There were some trials, say with Roger Pertwee, when he found out about 
anandamide; but if individuals could be helped in the ways they say they are, 
could this be proven or shown rather than, as it was, just their accounts of 
what had happened to them? We wanted to have some official recognition that 
this happened, to flesh out the people’s accounts of their experiences of how 
cannabis had helped them. I asked all these people to tell their doctor what had 
happened to them and to tell their local politician, to put it about to people 
that cannabis helped them. With requests or pestering by patients, eventually 
people tried to do trials to see if this could be authenticated in any way, whereas 
before it was just anecdotal evidence. 
139  Russo (2006).The Medicalization of Cannabis
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berridge: And you set up the Alliance for Cannabis Therapeutics (ACT)?
140 
hodges: Yes, I started that with a couple of other patients who found that 
cannabis was helpful.
141 I found them through the neurologist I see. I said: ‘I’ve 
found this very helpful. Do you know of any other patients with MS who also 
use it?’ And he did. So with those two, we decided to find more people who also 
used it. That’s what the alliance was set up for. 
berridge: How did you operate? How do you operate? 
hodges: How do we operate? By bringing it to everyone’s awareness, maybe 
through newspapers or television, just telling people at the time that I found this 
helpful, and other people did as well; that many people have found it relieved 
their pain. And so we asked: ‘Can someone do some trials on this to show if there 
is anything to it?’ Otherwise, it is only our personal experiences of cannabis. Is 
there any other way we could take it? So, that’s really why the alliance was set 
up: we wanted to draw people’s attention to the fact that cannabis helped us, 
and find out if anyone could authenticate this in any way. 
berridge: I think what’s come across in talking this afternoon has been the 
importance of patients and I wonder whether perhaps Victoria Hutchins would 
also like to say something? 
Ms Victoria hutchins: I was diagnosed with MS in 1997, when I was 19, so 
I’ve had it for about 12 years. The pain really started to come in about 2001 
and then got worse and worse. I was prescribed tablet after tablet: baclofen, 
gabapentin, tizanidine. I found that I couldn’t tolerate the side-effects for the 
amount of tablets I’d have to take. Then, a couple of years ago, I got referred to 
the pain clinic with Dr Notcutt, and he tried me on Nabilone, which was great. 
I wanted to increase the dose, but I found that I couldn’t think straight, I was 
slurring and I couldn’t have a proper conversation. It wasn’t working for me, so 
we tried Sativex; oh, it’s just changed my life. It’s changed my life, it really has. 
I can eat and sleep and the pain is less. It’s just changed my life. Yes and I went 
on a withdrawal study: you could have been given the placebo or Sativex, and 
I knew within about 12 hours that I had the placebo. The first day wasn’t too 
bad, but the second day it was like having boiling water poured down my legs, 
so I came off the study. 
140  Dr Clare Hodges established the British branch of the US Alliance for Cannabis Therapeutics in 1993. 
See http://marijuana-as-medicine.org/alliance.htm (visited 25 January 2010). 
141  The other two patients were Bill Thorton-Smith and Elizabeth Mcrory. The Medicalization of Cannabis
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notcutt:  Two things really: I wanted to pick up on something that Clare 
Hodges said because I got involved with Clare and the ACT, I think, in about 
1993 or 1994 because of a letter in the Guardian.
142 But I think one of the things 
that came across as I realized, starting to talk about this publicly, and starting 
to speak out, I found myself sort of putting my head above the parapet, and 
actually became the BMA’s unofficial spokesperson on this issue within about 
a year. They directed journalists to me and to Clare; we were forever getting 
journalists. I think it was one important factor that we, both of us, agreed that 
the first thing we would ever say to journalists, wherever, was: ‘There are two 
issues here, there is the recreational use of cannabis and there is the medicinal 
use.’ We kept on hammering this message home and I still do to this day, when 
they bother to come, so that we focused on the issue of cannabis as a medicine. 
If you want to look at it, you could compare it with opiates; street opiates and 
the medicinal use of opiates.
To pick up on Victoria’s issue here: she very quickly found out that all of her 
symptoms came back when she went into trial and withdrew after she’d been 
on Sativex for about a year. After about 12 to 18 hours her symptoms came 
back with a vengeance. I mean the boiling water going down your legs; it feels 
like boiling water down your legs; if you’ve ever had that happen to you, it is 
singularly unpleasant and several of her other symptoms worsened at the same 
time. We saw this with a number of patients who had been on this particular 
withdrawal study; when they went onto placebo their symptoms came back, 
often within 12 to 18 hours of discontinuing Sativex. 
holdcroft: I think activism played an important part in recruitment into our 
clinical trial. The positive activism by patients was very important to recruit 
people onto the study, but, on the other hand, there was also the negative 
activism, as Willy Notcutt has suggested, that patients who have had a bad 
experience, presumably by overdose, can influence other patients, who then 
refuse to go into clinical trials, particularly if they have not taken cannabis 
before. I can remember one particular time when a patient on our clinical study 
was saying how they felt and their partner came along and said: ‘Oh, you’ll feel 
differently, you’ll actually feel better, if you think this way.’ So there was one 
person altering the effect on another. I think that’s something to be discussed 
out in the public arena: how one person influences the pain of somebody else, 
or even influences consent to these types of studies.
142  Notcutt (1993).The Medicalization of Cannabis
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berridge: There’s almost a sense of a group of people already quite knowledgeable, 
who were then recruited onto trials? Patients who had experiences.
holdcroft: Yes, grannies and granddads who had missed the hippie culture in 
their youth were having second thoughts when their sons and daughters came 
along and said: ‘Oh, you must go on this study, you know, if you missed it when 
you were young, have it now!’ [Laughter]
Mechoulam: Let me tell you how we solved this problem, partially solved, of 
course. There was pressure on the Israeli parliament from patients to allow 
them to use cannabis. There was a committee appointed by parliament (around 
1995). I was the head of the committee, the others were people from the various 
ministries and I was the only one who came from the outside. There were a lot 
of things that we suggested: one of them was that medical cannabis should be 
allowed. This was never discussed in parliament because members of parliament, 
of course, didn’t want to appear in the newspapers: ‘They are for illicit drugs.’ 
But the Attorney General apparently accepted it, passed on his approval to the 
Ministry of Health, which has, for the last couple of years (since 2006), allowed 
the use of medical marijuana from a standardized source to patients. There is a 
committee with which I am partially involved, which has approved it for about 
300 patients. We think that we shall reach the number of 1000 patients within 
the next few years. The physician of each patient has to apply to the ministry, 
describing what the treatment has been so far, and that he recommends the use 
of medical marijuana. Then the committee or the Ministry of Health has to 
approve it. As I said, we have about 300 patients, mostly for Crohn’s disease, 
MS, bone marrow replacement therapy, post-trauma and rheumatoid arthritis. 
We get feedback from these patients and on the basis of this feedback, we shall 
allow more patients to go ahead. We’ve not solved the problem, but I think that 
we are moving in the right direction. 
Guy: I want to address two points: one that Anita Holdcroft brought up, of 
course, is to do with consent. It’s true to say that there are very few patients, if 
any at all, who go into a trial of a cannabis-based medicine and don’t have an 
opinion about what they’re about to take. Now, that’s very different from other 
pharmaceutical trials where you’re giving them a coded drug and the patients 
generally have little in the way of expectations. What you’ll find, and what we 
have certainly found in our trials, is that we have very, very high placebo rates in 
the placebo group, but also overall, and our experience now is over 3000 patients 
in randomized trials, that there isn’t unblinding, except in the end points that 
you’re looking for. There’s no unblinding in terms of the patient being able The Medicalization of Cannabis
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to determine whether they’re on active or placebo. That actually extends to 
both cannabis-naive and non-cannabis-naive patients. We don’t really see any 
difference in those. All we saw, I think, in the earlier studies was the cannabis-
experienced patients would titrate up to their optimal dose about a day earlier; 
in about seven days compared with the non-experienced, but they’d still end up 
on the same dose. So, the placebo experience is something you have to deal with 
and we’ve dealt with in more recent trials in a fairly special approach to the way 
we obtain consent. 
The other issue, and I know it’s come up a few times about grannies revisiting 
their youth and whatever: I think it’s very important for people not to leave 
with the thought that these patients are better because they’re stoned or they’re 
high. I’d use the word, disability,, and I know I got pulled up in the US for 
doing this, but I said: ‘I don’t want to swap one disability for another.’ I think 
Victoria Hutchins’s experience was that she found that she was – as she told 
me earlier – very incapacitated by some of the other medicines that she was 
on. What we have done in all these trials is to ask patients about the classic, 
cannabis-like  side-effects,  the  ones  that  worry  people;  the  reason  why  an 
enormous swathe of preclinical research is now looking at non-psychoactive or 
peripheral cannabinoids; strange really when most of their effects are central, of 
course. You may be interested to know, for example, if you take two symptoms, 
dizziness and euphoria – I think you’d relate those quite well to intoxication – 
you find overall, I think, that in Sativex trials the level of euphoria was about 3 
per cent. So if we were looking to create a euphoriant, we wouldn’t have done 
very well. In two trials the placebo was higher. In terms of dizziness: a lot of the 
drugs that patients would take for MS, gabapentin for example, cause dizziness, 
I think the average in the trials is around 34–35 per cent, a recent trial of Sativex 
we reported was 13 per cent with dizziness.
143 Those two classic, giggly-type 
effects you would expect from cannabis are very low. The third one is that we 
created a 100-point visual analogue scale for the patients to report on the extent 
of their intoxication. We used this in the early clinical trials, in the Phase I 
studies, where we did give some subjects some extremely high doses, and we also 
developed an inhaled route just to see if we could replicate the smoking route. 
Essentially, on a score of 0 to 100, if the subjects did not score above 80, then 
they didn’t have any particularly strong subjective experience of being high. So 
70 or 80 on that scale is into the high zone. I know that Philip Robson, when 
he gives lectures, says that: ‘If you buy street cannabis and you only get to 70, 
143  Johnson et al. (2010). See also Rathbone et al. (2009).The Medicalization of Cannabis
66
you’ll go and ask for your money back.’ The patients who enter our studies are 
all on multiple therapies. They’re on half-a-dozen drugs, some of them, and 
they will score at the beginning of these studies about six or seven out of 100. 
In the ensuing two weeks of titration where we’re asking them to titrate as far 
as they can to obtain benefit, but not have excessive side-effects, so we’d expect 
them, in successful titration, to experience some side-effects, they score up to 
about 14 out of 100. By two months, they’re down to about six, and by a year 
they’re down to three out of 100. 
One other thing I would like to say is that in thinking about cannabis-based 
medicines, I mean, thinking about other cannabinoids, the psychoactive effects, 
when used in the dosage and delivery regimen that we use, are simply not an 
issue, with regard to prohibition or with regard to not being able to proceed. 
There are a whole slew of other drugs that patients take, which will give far 
greater psychoactive effects on any particular day. You’ll find that patients with 
these medicines are able to go about their normal daily work: teachers, lawyers, 
stockbrokers,  and  also  adjust  their  dosage  around  it. There’s  an  important 
message: although we know cannabis in very high doses can cause what we 
would call overdose, these psychoactive effects simply aren’t an issue for patients 
in therapeutic doses.
notcutt: To pick up on the titration: as time has gone by, one has learnt to 
titrate this medicine very accurately and very carefully, and to get to the point 
where the patients want to be. I’m going to go back and ask Victoria Hutchins: 
how easy did you find it to titrate and to get the response that you want? 
hutchins:  With  the  others,  with  the  tablets  I  was  given  [notcutt:  That’s 
Nabilone], yes, I couldn’t choose when to have side-effects. But with Sativex – 
maybe I get a greater pain at 11 o’clock in the morning than I did yesterday, so 
I take it then. So I can just work it around my day.
notcutt: So you can fine-tune it and customize it to how you are, and to your 
activities in the day? I don’t want to put the words in your mouth.
edwards: Listening to this debate, I was wondering what the rules of evidence 
are;  we  haven’t  talked  enough  about  that. The  first  use  in  this  country  of 
penicillin was the giving of it to a police constable who was suffering from sub-
acute bacterial endocarditis. It was done in Oxford and the guy should have died, 
because people die of sub-acute bacterial endocarditis, but he survived.
144 It didn’t 
144  See Fletcher (1984); Booth (1995). The Medicalization of Cannabis
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need a controlled trial, people didn’t say: ‘Go away for ten more years, or, it’s not 
really safe to give it: what are the side-effects?’ So I don’t necessarily believe that 
controlled trials are everything and sometimes persuasive evidence of another 
kind is there before one’s eyes. And there are also, of course, quite bogus claims 
made on single cases. I deeply respect what our patients say, and I wish doctors 
would listen more often and more closely. But I also know that medicine was 
once founded on what doctors believed and patients told, and that really wasn’t 
enough. We also need the evidence of science and control for the placebo effect.
I am persuaded when Raphael Mechoulam tells me about 400 very ill children 
and no control.
145 I would accept that as evidence, and I don’t necessarily accept 
controlled trials: they can be badly designed. At best, they will tell me about 
effect size and they’ll tell me what the size is and not just if ‘it works’. What 
worries me is the irrationality sometimes of the opposition to good research, 
with some weakening of standards on what we take as the evidence here. I am 
left puzzled that the controlled trials building on the brilliant laboratory work 
on endogenous cannabinoids etc., hasn’t had its pinnacle in the application to 
clinical medicine. I feel it is a bit of a damp squib – well, that’s too harsh – but 
the squib perhaps hasn’t gone bang yet. I really would like to see more attention 
paid to the rules of evidence for our patients’ sake.
Russo: I’d like to follow that with an effort to create a little more context about 
cannabis and how it works. What we’ve got is a situation where, for all intents 
and purposes, if we’re talking about pain, everything we know about how to 
treat it has derived from plants. It may have started with Salix spp., salicylates, 
willow bark, which led to knowledge of the prostaglandins. We’ve heard about 
the opium poppy and then production of opiates, the discovery of endogenous 
opioids and enkephalins. The cannabinoids have led to the discovery of the 
cannabinoid receptors and the endocannabinoid system, which turns out to be 
a major homeostatic mechanism in the body. Just for context, people need to 
understand that there are more cannabinoid receptors in the central nervous 
system than there are for all neurotransmitters put together.
146 In the nervous 
system, it is a modulator; it’s not a neurotransmitter per se, but works on other 
systems to modify them. Going from a concept, a beautiful concept, that Raphael 
Mechoulam introduced about ten years ago, called the ‘entourage effect’: this was 
the fact that there are many seemingly inactive things that structurally resemble 
145  See page 59. 
146  See Pertwee (2002). The Medicalization of Cannabis
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endogenous  cannabinoids,  but  have  no  direct  apparent  effects  themselves.
147 
However, when they’re present with other active endocannabinoids, they can 
synergize to a great degree. An example would be palmitoyl-ethanolamide, which 
increases the analgesic effects of endocannabinoids 100-fold.
148 This is the kind of 
thing that we have to know to understand how the plant may work too. This is, 
again, speaking against the concept of single, molecular medicine and advocating 
synergistic phytomedicine. I think we’re beginning to see more examples. One 
from a current clinical trial with Sativex would be in a cancer pain clinical trial 
that happened some years ago.
149 At that point, a high THC extract was being 
tested and Sativex, with THC and CBD, as well as the other components, versus 
placebo, because at the time no one was sure which preparation would be best. 
In fact, it was thought that both would probably work. What turned out to be 
the case for people with severe intractable cancer pain was that the placebo didn’t 
work. Surprisingly, the high THC extract didn’t work any better than placebo, but 
Sativex, with THC and CBD together, as well as other components, worked quite 
well.
150 In fact, about 43 per cent of patients who were previously intractable had a 
30 per cent or better decrement in their pain, and this is the current gold standard 
for regulators.
151 We’re beginning to see a situation in which it can be proven that 
sometimes nature does it better even than our biosynthetic chemists, who for a 
long time have had this lock-and-key model, where we know the receptor and 
what we therefore do is design a molecule which binds to it with the highest 
possible affinity and the greatest possible potency.
152 That isn’t the way nature 
works: we’re dealing with a system that has a certain static level of activity and if 
it is out of balance, too high or too low, nature will try to bring it back into the 
middle. This is what we think phytocannabinoids also are capable of doing on a 
therapeutic level.
153
Robson: Could I directly address Griffith Edwards’s point?
154 I think that the 
standard has to be consistent, and I agree with you that that standard has to be 
147  Ben-Shabat et al. (1998).
148  Calignano et al. (1998).
149  Johnson et al. (2010).
150  Russo and Guy (2006).
151  Russo (2008).
152  McPartland and Russo (2001). 
153  Russo (2004a).
154  See pages 66–7. The Medicalization of Cannabis
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approached and it hasn’t been fully reached yet, for very good reasons. I think 
that if you take the areas in particular that have been looked at for cannabinoid 
medicine so far; let’s take spasticity, for example: if you look at the level of 
evidence that supports the drugs that are currently prescribed for this, you’ll find 
they’re surprisingly weak. Several of the drugs that are licensed in this indication 
haven’t been proved against the so-called gold standard measure in spasticity 
and it’s quite shocking to see how weak the evidence is for those drugs. In terms 
of large-scale, well-planned clinical trials on cannabis-based medicines, these are 
very early days. I think GW is a very innovative company, if I could say that, 
but it’s a very small company and the level of resource that has been available 
to carry out clinical trials has been, to some extent, limited. The measures, the 
outcome measures, that we are dealing with are very inexact. There are many 
difficulties in the basic design of these studies. This, I think, explains why it’s 
taking seemingly a long time to match in the clinical context what we’ve seen in 
the laboratory, but I’m absolutely confident, based on the results that are now 
emerging, not just from GW but from elsewhere, that these data will come. 
And I agree with you: there should be no lowering of the requirement of proof 
for these medicines. 
hodges: I would like to ask everybody about the downside of cannabis, because 
I’ve become more and more aware of the downsides, as we can see with young 
teenagers, because I can see that it’s affecting my mind; not that it’s making me 
psychotic, but I’m very conscious of it affecting my mind as well as helping my 
body. Has anyone studied this?
Robson: As the token psychiatrist, perhaps I could mention, what has happened 
is that there have been a number of long-term, well-planned studies which have 
identified children before they start using a drug, followed them through to 
adulthood and tested the correlation or the link, or the increase in risk, of a 
psychotic episode later in life, which is associated with smoking cannabis at a 
young age. There has been a fairly consistent demonstration that that risk is 
increased.
155 However, it has to be said that the methodology of all of those trials 
is, to some extent, questionable. There are great complications in carrying out 
such studies, not least in terms of confounding factors, outcome measures, the 
difficulty of relying on self-reported, subjective information about the drugs 
that are being taken and whether people are still continuing to take cannabis, 
when in fact they’re saying they’re not, at the outcome stage. So, although the 
general consensus is that smoking cannabis, especially at a very young age, 
155  See Moore et al. (2007).The Medicalization of Cannabis
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increases the risk of developing a psychotic condition in later life, the level 
of risk as assessed, for example, by an independent body such as the ACMD, 
is low. It’s important to bear in mind that the doses being used by people in 
the recreational context, as has been touched on before, are much higher in 
terms of brain levels than those being used by medical patients who are doing 
their very best to avoid intoxication and, as we’ve heard, have very low levels 
of so-called psychotic, unwanted effects such as hallucinations, paranoid ideas 
or indeed psychotic states. I think, again, that we have to separate recreational 
use from medicinal use. I think the answer is that the evidence suggests that 
in the recreational area, there is a risk, albeit a small one, and that the risk 
is likely to be much lower in the medicinal field. I would also say that when 
one is assessing risk it should never be in a vacuum. In the case of recreational 
drugs, one should always look at the relative risk of other drugs for causing the 
same effect, and it’s certainly by no means just cannabis that may be associated 
with the risk of developing psychotic illnesses. Stimulants and hallucinogens 
have been investigated in the past. There are many other recreational drugs 
which carry, I suspect, an equal or greater risk than cannabis and, equally, in 
the medicinal context one shouldn’t look at the risk of cannabis in producing 
psychiatric or any other adverse event in a vacuum, it should be relative to the 
risks of other medicines that are currently licensed. 
Guy: Two little points there: you may be interested to know that a major global 
research collaboration we have with cannabis extracts is actually looking at the 
treatment of schizophrenia at the moment, so it goes both ways actually, that 
issue.
156 Can I just address the question? If I understood, what you proposed is 
that perhaps with all of the stigma around cannabis, people’s standards and the 
hurdles may have been dropped or confused a bit. I think, actually, from our 
point of view, having dealt with regulators in most continents, with clinical 
trials at the moment running in 18 countries, so we have a lot of experience 
in most countries throughout the world, Sativex is being used in 22 countries, 
it’s absolutely the opposite. If anything, the hurdles have been raised, because 
any of the regulators’ decisions to do with Sativex are very, very public, even 
to the extent that, as you know, a year and a half ago, the MHRA took the 
unprecedented step of publishing a public information report on Sativex, on 
a medicine which was not under application at the time, and this is absolutely 
156  See Roser et al. (2008). Dr Geoffrey Guy wrote: ‘My reference to collaboration is our global research 
collaboration with Otsuka Pharmaceuticals from Japan, which covers the research and development by GW 
of a range of our cannabinoids in the fields of neuropsychopharmacology, oncology and pain.’ E-mail to Ms 
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unique.
157 The basis was that of the great amount of public interest and the 
extent of usage. So, I can absolutely assure you that there are no short cuts; there 
are no easy ways. Having spent nearly six years trying to get Sativex approved in 
the UK, I can guarantee that the quality of data required by the regulators and/
or indeed the publishers of the journals in which the study has been published, 
has, in our mind, not been lowered in any way whatsoever. In fact, possibly 
raised slightly. 
berridge: I think on that point, bringing in the dual nature of cannabis, which 
is where we started, we will finish and we’ll see how that duality develops in 
future years. Thank you all very much indeed for coming and for giving us 
what I think has been an excellent discussion and we look forward to seeing the 
transcription. 
Tansey: I would like to add my thanks to all of you for coming here today. I 
hope you will now join all of us, the team, Virginia, Suzanne, and Lois, Ania 
and Wendy, who have been manning the microphones, for a glass of wine.
157  MHRA (2007). The Medicalization of Cannabis – Appendix 1
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Appendix 1
diagrams of the structures of some major plant cannabinoids and of 
certain structurally related synthetic cannabinoids
adapted from Pertwee (2006): 165 and Pertwee (ed.) (2005): 3.
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